SEC Info - Innerscope Hearing Technologies, Inc.

SEC Info℠

Home

Help

Please Sign In

Innerscope Hearing Technologies, Inc. – ‘10-K’ for 12/31/20

On: Wednesday, 9/14/22, at 8:00am ET · For: 12/31/20 · Accession #: 1554795-22-341 · File #: 0-55754

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/14/22  Innerscope Hearing Techs, Inc.    10-K       12/31/20   64:6.2M                                   Sharello Corp./FA

Annual Report — Form 10-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   1.31M 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     25K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     24K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     20K 
10: R1          Cover                                               HTML     76K 
11: R2          Consolidated Balance Sheets                         HTML    141K 
12: R3          Consolidated Balance Sheets (Parenthetical)         HTML     42K 
13: R4          Consolidated Statements of Operations               HTML    116K 
14: R5          Consolidated Statement of Changes in Stockholders'  HTML     55K 
                Deficit                                                          
15: R6          Consolidated Statements of Cash Flows               HTML    116K 
16: R7          Note 1 - Organization                               HTML     22K 
17: R8          Note 2 - Summary of Significant Accounting          HTML     84K 
                Principles                                                       
18: R9          Note 3 - Going Concern and Management's Plans       HTML     24K 
19: R10         Note 4 - Intangible Assets, Net (Other Than         HTML     29K 
                Goodwill)                                                        
20: R11         Note 5 - Note Payable, Stockholder                  HTML     25K 
21: R12         Note 6 - Note Payable                               HTML     27K 
22: R13         Note 7 - Related Party Transactions                 HTML     29K 
23: R14         Note 8? Investment in Undivided Interest in Real    HTML     43K 
                Estate                                                           
24: R15         Note 9? Convertible Notes Payable - Undivided       HTML     76K 
                Interest in Real Estate                                          
25: R16         Note 10 - Derivative Liabilities                    HTML     29K 
26: R17         Note 11? Commitments and Contingencies              HTML     37K 
27: R18         Note 12? Income Taxes                               HTML     35K 
28: R19         Note 13 - Stockholders? Equity                      HTML     34K 
29: R20         Note 14 - Risks and Uncertainties                   HTML     22K 
30: R21         Note 15 - Business Acquisition                      HTML    271K 
31: R22         Note 16 - Subsequent Events                         HTML     39K 
32: R23         Note 2 - Summary of Significant Accounting          HTML    129K 
                Principles (Policies)                                            
33: R24         Note 2 - Summary of Significant Accounting          HTML     49K 
                Principles (Tables)                                              
34: R25         Note 4 - Intangible Assets, Net (Other Than         HTML     26K 
                Goodwill) (Tables)                                               
35: R26         Note 5 - Note Payable, Stockholder (Tables)         HTML     24K 
36: R27         Note 7 - Related Party Transactions (Tables)        HTML     25K 
37: R28         Note 8? Investment in Undivided Interest in Real    HTML     39K 
                Estate (Tables)                                                  
38: R29         Note 9? Convertible Notes Payable - Undivided       HTML     30K 
                Interest in Real Estate (Tables)                                 
39: R30         Note 10 - Derivative Liabilities (Tables)           HTML     27K 
40: R31         Note 11? Commitments and Contingencies (Tables)     HTML     25K 
41: R32         Note 12? Income Taxes (Tables)                      HTML     31K 
42: R33         Note 15 - Business Acquisition (Tables)             HTML    271K 
43: R34         Customers who accounted for more than ten percent   HTML     26K 
                of the Company's revenues and accounts receivable                
                balances (Details)                                               
44: R35         Property and equipment (Details)                    HTML     33K 
45: R36         Financial instruments measured at fair value on a   HTML     32K 
                recurring basis (Details)                                        
46: R37         Note 3 - Going Concern and Management's Plans       HTML     36K 
                (Details Narrative)                                              
47: R38         Intangibles (Details)                               HTML     33K 
48: R39         Amounts stockholder loaned the Company and amounts  HTML     23K 
                repaid (Details)                                                 
49: R40         Expenses to officers (Details)                      HTML     25K 
50: R41         Consolidated balance sheets and statement of        HTML    130K 
                operations for the real property (Details)                       
51: R42         Future principal payments for the Company's         HTML     31K 
                portion of real property (Details)                               
52: R43         Summary of convertible note balances (Details)      HTML     26K 
53: R44         Summary of activity related to derivative           HTML     28K 
                liabilities (Details)                                            
54: R45         Future principal payments for operating lease       HTML     34K 
                expenses (Details)                                               
55: R46         Provision for income taxes (Details)                HTML     28K 
56: R47         Net deferred tax assets (Details)                   HTML     25K 
57: R48         Fair value of assets, liabilities and intangible    HTML     83K 
                assets and purchase price allocation (Details)                   
58: R49         Pruchase consideration of the Company's common      HTML     23K 
                stock value (Details)                                            
59: R50         Unaudited pro forma condensed financial statements  HTML    355K 
                (Details)                                                        
62: XML         IDEA XML File -- Filing Summary                      XML    113K 
60: XML         XBRL Instance -- innd0901form10k_htm                 XML   1.41M 
61: EXCEL       IDEA Workbook of Financial Reports                  XLSX    132K 
 6: EX-101.CAL  XBRL Calculations -- innd-20201231_cal               XML    142K 
 7: EX-101.DEF  XBRL Definitions -- innd-20201231_def                XML    290K 
 8: EX-101.LAB  XBRL Labels -- innd-20201231_lab                     XML    735K 
 9: EX-101.PRE  XBRL Presentations -- innd-20201231_pre              XML    605K 
 5: EX-101.SCH  XBRL Schema -- innd-20201231                         XSD    105K 
63: JSON        XBRL Instance as JSON Data -- MetaLinks              294±   423K 
64: ZIP         XBRL Zipped Folder -- 0001554795-22-000341-xbrl      Zip    259K

‘10-K’ — Annual Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C: C: C: C: C: C: C: C: C:

i 0001609139 i false i true i FY i 2020 i --12-31 i true i true i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i 4953692 i 10395547 i 19250160 i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i i 0001609139 2020-01-01 2020-12-31 0001609139 2019-09-30 0001609139 2022-08-22 0001609139 2020-12-31 0001609139 2019-12-31 0001609139 us-gaap:SeriesAPreferredStockMember 2020-12-31 0001609139 us-gaap:SeriesAPreferredStockMember 2019-12-31 0001609139 us-gaap:SeriesBPreferredStockMember 2020-12-31 0001609139 us-gaap:SeriesBPreferredStockMember 2019-12-31 0001609139 2019-01-01 2019-12-31 0001609139 us-gaap:PreferredStockMember 2018-12-31 0001609139 us-gaap:CommonStockMember 2018-12-31 0001609139 us-gaap:DeferredCompensationShareBasedPaymentsMember 2018-12-31 0001609139 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001609139 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001609139 us-gaap:RetainedEarningsMember 2018-12-31 0001609139 2018-12-31 0001609139 us-gaap:PreferredStockMember 2019-01-01 2019-12-31 0001609139 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001609139 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-01-01 2019-12-31 0001609139 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001609139 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001609139 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001609139 us-gaap:PreferredStockMember 2020-01-01 2020-12-31 0001609139 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001609139 us-gaap:DeferredCompensationShareBasedPaymentsMember 2020-01-01 2020-12-31 0001609139 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001609139 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001609139 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001609139 us-gaap:PreferredStockMember 2019-12-31 0001609139 us-gaap:CommonStockMember 2019-12-31 0001609139 us-gaap:DeferredCompensationShareBasedPaymentsMember 2019-12-31 0001609139 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001609139 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001609139 us-gaap:RetainedEarningsMember 2019-12-31 0001609139 us-gaap:PreferredStockMember 2020-12-31 0001609139 us-gaap:CommonStockMember 2020-12-31 0001609139 us-gaap:DeferredCompensationShareBasedPaymentsMember 2020-12-31 0001609139 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001609139 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001609139 us-gaap:RetainedEarningsMember 2020-12-31 0001609139 INND:CustomerConcentration1RiskMember 2020-01-01 2020-12-31 0001609139 INND:CustomerConcentration1RiskMember 2019-01-01 2019-12-31 0001609139 INND:CustomerConcentration2RiskMember 2020-01-01 2020-12-31 0001609139 INND:CustomerConcentration2RiskMember 2019-01-01 2019-12-31 0001609139 us-gaap:FairValueInputsLevel1Member 2019-12-31 0001609139 us-gaap:FairValueInputsLevel2Member 2019-12-31 0001609139 us-gaap:FairValueInputsLevel3Member 2019-12-31 0001609139 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001609139 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001609139 us-gaap:FairValueInputsLevel3Member 2020-12-31 0001609139 srt:ChiefExecutiveOfficerMember 2020-01-01 2020-12-31 0001609139 srt:ChiefExecutiveOfficerMember 2019-01-01 2019-12-31 0001609139 srt:ChiefFinancialOfficerMember 2020-01-01 2020-12-31 0001609139 srt:ChiefFinancialOfficerMember 2019-01-01 2019-12-31 0001609139 us-gaap:PartiallyOwnedPropertiesMember 2020-12-31 0001609139 us-gaap:PartiallyOwnedPropertiesMember 2019-12-31 0001609139 us-gaap:PartiallyOwnedPropertiesMember 2020-01-01 2020-12-31 0001609139 us-gaap:PartiallyOwnedPropertiesMember 2019-01-01 2019-12-31 0001609139 us-gaap:PaymentGuaranteeMember 2020-01-01 2020-12-31 0001609139 INND:AllocationOfPurchasePriceMember 2021-11-22 0001609139 2021-11-22 0001609139 2021-01-01 2021-12-31 0001609139 INND:CompanyMember 2020-12-31 0001609139 INND:AcquisitionMember 2020-12-31 0001609139 us-gaap:ScenarioAdjustmentMember 2020-12-31 0001609139 srt:ProFormaMember 2020-12-31 0001609139 INND:CompanyMember 2020-01-01 2020-12-31 0001609139 INND:AcquisitionMember 2020-01-01 2020-12-31 0001609139 us-gaap:ScenarioAdjustmentMember 2020-01-01 2020-12-31 0001609139 srt:ProFormaMember 2020-01-01 2020-12-31 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM i 10-K

(Mark One)

☑

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended i December 31, 2020

i ☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: i 000-1609139

i INNERSCOPE HEARING TECHNOLOGIES, INC.

(Exact name of registrant as specified in its charter)


i Nevada		i 46-3096516
(State or other jurisdiction of incorporation or organization)		(I.R.S. Employer Identification No.)

i 2151 Professional Drive, i Second Floor
i Roseville, i CA		i 95661
(Address of principal executive offices)		(Zip Code)

( i 833) i 788-0506

(Registrant’s telephone number, including area code)

Securities registered under Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act: Common Stock, $0.0001 par value

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ i No ☑

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ i No ☑

Indicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or has for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☐ i No ☑

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). i Yes ☑ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☑

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐

Accelerated filer ☐

i Non-accelerated filer ☐

Smaller reporting company ☑

(Do not check if a smaller reporting company)

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. i ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes ☐ i No ☑

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter was $ i 4,752,400 as of September 30, 2019

The number of shares outstanding of the registrant’s $0.0001 par value Common Stock as of August 22, 2022, 2022, was i 7,662,715,566 shares.

Table of Contents

	PART I	Page

Item 1	Business	4
Item 1A	Risk Factors	6
Item 1B	Unresolved Staff Comments	15
Item 2	Properties	15
Item 3	Legal Proceedings	16
Item 4	Mine Safety Disclosures	16

	PART II

Item 5	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities	17
Item 6	Selected Financial Data	17
Item 7	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
Item 7A	Quantitative and Qualitative Disclosures About Market Risk	22
Item 8	Financial Statements and Supplementary Data	22
Item 9	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure	22
Item 9A	Controls and Procedures	22
Item 9B	Other Information	23

	PART III

Item 10	Directors, Executive Officers and Corporate Governance	24
Item 11	Executive Compensation	26
Item 12	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	27
Item 13	Certain Relationships and Related Transactions, and Director Independence	28
Item 14	Principal Accountant Fees and Services	28

	PART IV

Item 15	Exhibits and Financial Statement Schedules	28
	Signatures	31

C: 2

FORWARD-LOOKING STATEMENTS

This report contains forward-looking statements. The Securities and Exchange Commission (the “SEC”) encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This report and other written and oral statements that we make from time to time contain such forward-looking statements that set out anticipated results based on management’s plans and assumptions regarding future events or performance. We have tried, wherever possible, to identify such statements by using words such as “project”, “believe”, “anticipate”, “plan”, “expect”, “estimate”, “intend”, “should”, “would”, “could”, or “may”, or other such words, verbs in the future tense and words and phrases that convey similar meaning and uncertainty of future events or outcomes to identify these forward–looking statements. There are a number of important factors beyond our control that could cause actual results to differ materially from the results anticipated by these forward–looking statements. While we make these forward–looking statements based on various factors and using numerous assumptions, you have no assurance the factors and assumptions will prove to be materially accurate when the events they anticipate actually occur in the future. Factors that could cause our actual results of operations and financial condition to differ materially are discussed in greater detail under Item 1A, “Risk Factors” of this annual report on Form 10-K.

The forward–looking statements are based upon our beliefs and assumptions using information available at the time we make these statements. We caution you not to place undue reliance on our forward–looking statements as (i) these statements are neither predictions nor guaranties of future events or circumstances, and (ii) the assumptions, beliefs, expectations, forecasts and projections about future events may differ materially from actual results. We undertake no obligation to publicly update any forward–looking statement to reflect developments occurring after the date of this report.

PART I

ITEM 1. BUSINESS.

Company Overview

InnerScope Hearing Technologies, Inc. (“InnerScope” or the “Company”) is a Nevada Corporation incorporated June 15, 2012, with its principal place of business in Roseville, California.

On June 20, 2012, InnerScope acquired InnerScope Advertising Agency, LLC (“ILLC”), a commonly owned entity, to provide advertising/marketing services to the hearing device industry in accordance with an Acquisition and Plan of Share Exchange with ILLC.

On November 1, 2013, InnerScope acquired Intela-Hear, LLC (“Intela-Hear”), a commonly owned entity, with an Acquisition and Plan of Share Exchange with Intela-Hear.

On August 25, 2017, the Company changed its name to InnerScope Hearing Technologies, Inc. to better reflect the Company's current direction as a hearing health technology company that manufactures, develops, distributes, and sells numerous innovative hearing health-related products, hearing treatments, and hearing solutions direct to consumer (DTC) with a scalable business model. The Company began offering its own line of FDA (Food and Drug Administration) registered Hearing Aids and its “Hearable”, and “Wearable” Personal Sound Amplifier Products (PSAPs). On July 5, 2018, the Company signed a supplier agreement as a direct shipped vendor ("DSV") for Walmart.com. The Company has been accepted as a Walmart.com USA, LLC (a wholly-owned subsidiary of Wal-Mart Stores, Inc.) supplier and will sell its FDA-Registered Hearing Aids and its PSAP to Walmart.com as the retailer for their Direct-To-Consumer online retail sale.

The Company is a manufacturer and a distributor/retailer of Direct-to-Consumer ("DTC") FDA (Food and Drug Administration) registered hearing aids, personal sound amplifier products (PSAPs), hearing-related treatment therapies, and doctor-formulated dietary hearing supplements (“Hearing Products”). The Company's mission is to improve the quality of life of the 70 million people in North America and the 1.5 billion people worldwide who suffer from hearing impairment and/or hearing-related issues. The management team of InnerScope is applying decades of industry experience and believes it is well-positioned with its innovative in-store point-of-sale Free Self-Check Hearing Screening Kiosks ("Hearing Kiosks") to directly benefit when the Over-the-Counter (OTC) Hearing Aid Act (the "OTC Hearing Aid Law") (see below “Proposed Rule for OTC Category for Hearing Aids”) becomes enacted (expected in 4^th quarter of 2022) (the OTC Hearing Aid Law allows OTC hearing aids for mild to moderate hearing losses to be sold in retail stores without a prescription or having to see a professional). The Hearing Kiosk is designed for the tens of millions of Americans with undetected/untreated mild-to-moderate hearing losses to treat themselves with the Company's easy, convenient, and affordable hearing products.

On September 10, 2018, the Company acquired all of the assets and assumed certain liabilities of Kathy L Amos Audiology (“Amos Audiology”) in exchange for 340,352 shares of common stock (the “Acquisition”). Amos Audiology provides retail hearing aid sales and audiological services in the East Bay area of San Francisco.

On September 30, 2021, the Company entered into an Asset Purchase agreement with iHear Medical, Inc. pursuant to which the Company received a number of intangible assets, equipment, customer database and inventory for total consideration of 400,000 preferred series C shares and a $1,000,000 convertible note, where preferred shares were valued at $666,667 on the day of purchase. As part of the acquisition, the Company assumed assets in the amount of $1,666,667, consisting of inventory, equipment, customer lists, patents and other technology-based intangibles.

We are dedicated to serving the retail hearing aid dispensing community and developing a program to contribute to various hearing aid focused charities.

InnerScope is an “emerging growth company” within the meaning of the federal securities laws. For as long as we are an emerging growth company, we will not be required to comply with the requirements that are applicable to other public companies that are not “emerging growth companies” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, the reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and the exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We intend to take advantage of these reporting exemptions until we are no longer an emerging growth company.

InnerScope will continue to be an emerging growth company until the earliest occurrence of (1) the last day of the fiscal year during which we have total annual gross revenues of at least $1billion (as indexed for inflation), (2) the last day of the fiscal year following the fifth anniversary of the date of our initial public offering, (3) the date on which we have, during the previous three-year period, issued more than $1 billion in non-convertible debt and (4) the date on which we are deemed to be a “large accelerated filer,” as defined under the Securities Exchange Act of 1934, as amended (which we refer to as the “Exchange Act”).

InnerScope also qualifies as a “smaller reporting company” under Rule 12b-2 of the Securities Exchange Act of 1934, as amended, which is defined as a company with a public equity float of less than $75 million. To the extent that we remain a smaller reporting company at such time as we are no longer an emerging growth company, we will still have reduced disclosure requirements for our public filings, some of which are similar to those of an emerging growth company including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and the reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements.

Our authorized capital stock currently consists of 14,975,000,000 shares of common stock, and 25,000,000 shares of preferred stock. Our common stock is listed on The OTCQB under the symbol “INND.”

Our principal corporate headquarters is located at 2151 Professional Drive, Second Floor, Roseville, CA. 95661. Our telephone number is (916) 218-4100. Our website address is www.innd.com. (The information contained on, or that can be accessed through, our website is not a part of this Annual Report on Form 10-K.)

Company’s Business Model

The Company's Hearing Products and its business model allow breaking through the persistent barriers that prevent access to effective hearing solutions. For example, the Company's recent acquisition of iHear Medical Inc., a DTC cloud-based hearing solution provider, gives access to over 40 patents and an FDA-registered manufacturing and R&D facility. In addition, the Company has acquired HearingAssist, an established leader in the direct-to-consumer hearing aid market with a customer base of over 400,000. These acquisitions, combined with a partnership with Atlazo Inc., a semiconductor innovator for next-generation AI smart devices, will allow the Company to take the lead position in the direct-to-consumer hearing solutions market by selling innovated proprietary advanced hearing products through Walmart and other major Big Box retailers.

The Company's full line of FDA-Registered Hearing Aids, PSAPs and Hearing Health products (“Hearing Products”) are currently available through multiple retail/wholesale channels: Walmart, Walmart.com, Walmart Canada, RiteAid.com, BestBuy.com, Amazon.com, Giant Eagle, Hy-Vee, Hartig Drug, Food City, and Cardinal Health dba RGH Enterprises Inc., which provides the Company's products to FSAStore.com, HSAStore.com, and WellDeservedHealth.com. In addition, the Company's Hearing Products will soon be available with more major retailers and pharmacy chains for in-store and online purchases.

Competition

We have numerous direct, indirect and partial competitors, many of which have valuable industry relationships and access to greater resources than we do. There is no assurance that we will be able to provide services that will be competitive in the marketplace, and even if competitive, that we will be able to earn a profit.

The internet is fast becoming a major factor in the distribution of hearing aids. In the U.S. numerous companies are on the internet advertising hearing aids at inexpensive prices. We compete directly with these internet companies which are similar to our business model, and to include Listen Lively, Audicus, and Eargo. In addition, the hearing device industry is controlled by 5 global manufacturers. These manufacturers are GN Store Nord, Sonova, Starkey Hearing Technologies, William Demant and WS Audiology, all of which have established products and substantially greater financial, sales and marketing, manufacturing and development resources than we possess. We also compete against traditional brick and mortar retail hearing clinics which primarily sells the 5 global manufacturers products.

Intellectual Property

With our asset purchase of iHear Medical Inc. we acquired access rights and license to over 40 U.S. patents for hearing aid technology. This includes 100% ownership to the only FDA-Cleared in-home hearing test, called the iHearTest. We also have numerous copyrights, trademarks, and inventions assignment agreements to protect our intellectual property rights. We have two provisional patents filed that may not result in issued patents. We cannot be certain that any of the steps we have taken will prevent the misappropriation of our intellectual property, particularly in foreign countries where the laws may not protect our proprietary rights in these countries as fully as in the United States.

Government Regulation.

We are subject to a limited variety of local, state, and federal regulations. Some of our products for example are registered with the U.S. Food and Drug Administration (the “FDA”), which regulates, among other things, the research, development, testing, design, manufacturing, approval, labeling, storage, recordkeeping, advertising, promotion and marketing, distribution, post approval monitoring and reporting and import and export of medical devices in the United States to assure the safety and effectiveness of medical products for their intended use. The U.S. Federal Trade Commission (the “FTC”) also regulates the advertising of our products in the United States. Further, we are subject to laws directed at preventing fraud and abuse, which subject our sales and marketing, training, and other practices to government scrutiny.

While we believe that our operations are in compliance with all applicable regulations, there can be no assurances that from time-to-time unintentional violations of such regulations will not occur. We are also subject to federal, state and local laws and regulation applied to businesses, such as payroll taxes on the state and federal levels. Our current business requires that we comply with state corporate filings, city or county business license and the necessary business liability insurance. The requirements of these regulations are minimal and do not cause any undue burden.

However, internet access and online services are not subject to direct regulation in the United States. Changes in the laws and regulations relating to the telecommunications and media industry, however, could impact our business. For example, the Federal Communications Commission could begin to regulate the Internet and online service industry, which could result in increased costs for us. The laws and regulations applicable to the Internet and to our services are evolving and unclear and could damage our business. There are currently few laws or regulations directly applicable to access to, or commerce on, the Internet. Due to the increasing popularity and use of the Internet, it is possible that laws and regulations may be adopted, covering issues such as user privacy, defamation, pricing, taxation, content regulation, quality of products and services, and intellectual property ownership and infringement. Such legislation could expose us to substantial liability as well as dampen the growth in use of the Internet, decrease the acceptance of the Internet as a communications and commercial medium, or require us to incur significant expenses in complying with any new regulations.

Regulation by the FDA

The FDA classifies hearing aids hearing aids as medical devices. In the United States, the Federal Food, Drug, and Cosmetic Act (the “FDCA”), as well as FDA regulations and other federal and state statutes and regulations, govern, among other things, medical device design and development, preclinical and clinical testing, device safety, premarket clearance and approval, establishment registration and device listing, manufacturing, labeling, storage, record-keeping, advertising and promotion, sales and distribution, export and import, recalls and field safety corrective actions, and post-market surveillance, including complaint handling and medical device reporting of adverse events.

We currently market and in compliance with the FDA regulations for our hearing aid products.

Proposed Rule for OTC Category for Hearing Aids

The FDA Reauthorization Act of 2017 (“FDARA”), which was signed into law on August 18, 2017 (the “OTC Hearing Aid Act”) created a new category of over-the-counter (“OTC”) hearing aids that are intended to be available without supervision, prescription, or other order, involvement or intervention of a licensed practitioner. The language in FDARA is not self-implementing, which means that the OTC hearing aid category does not exist until there is effective regulation. On October 20, 2021, the FDA published a notice of proposed rulemaking to establish new regulatory categories for OTC and prescription hearing aids, among other things (the “Proposed Rule”). Under FDARA, the OTC hearing aid controls that are the subject of the rulemaking, if finalized, would preempt any state or local requirement specifically related to hearing products that would restrict or interfere with commercial activity involving OTC hearing aids. The comment period on the Proposed Rule, in which we participated in support of the Proposed Rule, ended on January 18, 2022, after which the FDA will review the comments. It is not clear whether the FDA will publish a final rule (the “Final Rule”), and whether the Final Rule will differ significantly from the Proposed Rule. However, if the FDA publishes a Final Rule, it would become effective 60 days after publication.

Under the Proposed Rule, devices that require 510(k) clearance to be compliant with the rule requirements would need to be cleared by the effective date of the Final Rule in order to continue to be marketed. For all other currently marketed devices, the proposed compliance date is 180 days after the effective date of the Final Rule (240 days after the publication of the Final Rule). Hearing aids under existing regulations at 21 CFR 874.330 and 874.3305, both of which are exempt from 510(k) premarket review.

Debt and Recent Events

Capital Raising

During the year ended 2020 and through July 30, 2022, we incurred an aggregate of $300,117 of convertible indebtedness, at variable conversion rates. An aggregate of $3,286,270 was outstanding as of December 31, 2020, convertible into approximately 4,650,000,000 shares of our common stock as of the date hereof. All of these financings were private transactions with accredited investors pursuant to Regulation D of Rule 506 or other exemptions from the registration requirements of the Securities Act.

Employees

As of June 24, 2022 we have 24 full-time employees.

ITEM 1A – RISK FACTORS

You should carefully consider the risks described below, as well as other information provided to you in this document, including information in the section of this document entitled “Forward-Looking Statements.” The risks and uncertainties described below are not the only ones facing the Company. If any of the following risks actually occur, the Company’s business, financial condition or results of operations could be materially adversely affected.

Investors should not place undue reliance on any such forward-looking statements. Further, any forward-looking statement speaks only as of the date on which such statement is made, and we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of anticipated or unanticipated events or circumstances. Our business, financial condition, and/or results of operation may be materially adversely affected by the nature and impact of these risks. New factors emerge from time to time, and it is not possible for us to predict all such factors. Further, we cannot assess the impact of each such factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Risks Related to Our Business and Our Industry

Our independent auditors have expressed substantial doubt about our ability to continue as a going concern.

We incurred net losses of $4,953,692 and $7,924,339 for the years ending December 31, 2020, and 2019, respectively. Because of the operating losses, negative cash flows from operations and working capital deficit, in their report on our financial statements for the year ended December 31, 2020, our independent auditors included an explanatory paragraph regarding their substantial doubt about our ability to continue as a going concern. We are dependent therefore in raising additional capital in order to fund our operations. We may continue to experience net operating losses in the foreseeable future. Our ability to continue as a going concern is subject to our ability to generate a profit and/or obtain necessary funding from outside sources, including obtaining additional funding from the sale of our securities, increasing sales, or obtaining loans from various financial institutions where possible. Our continued net operating losses increase the difficulty in meeting such goals and there can be no assurances that such methods will prove successful.

We are dependent on raising additional capital. If we are unable to raise additional capital, we may not be able to achieve our business plan and you could lose your investment.

We are dependent on raising outside capital to fill our operational and expansion needs. We currently raise this debt through private debt or equity financings, as well as obtaining credit from vendors to be able to fully execute our business plan. Any additional capital raised through the sale of equity may dilute your ownership interest. We may not be able to raise additional funds on favorable terms, or at all. If we are unable to obtain additional funds or credit from our vendors, we will be unable to execute our business plan and you could lose your investment. Management estimates we will need approximately $2,500,000 to fully implement, execute, market and launch our plans of multiple revenue streams in 2021. During 2021 we raised approximately $3,074,00 by the issuance of convertible notes.

Our Directors and Officers hold 900,000 Shares of our Series B Preferred Shares which gives them voting control of the Company and therefore effective control of the Company.

As the holders of the Series B Preferred Stock, our current officers and directors (the Moores) will have 1,000 votes per each share of the 900,000 shares of Series B Preferred that they own, constituting 900,000,000 votes, on any matter submitted to the holders of the common stock of the Company, effectively giving the holders voting control of the Company, as there are only 3,628,422,042 shares of the Company’s common stock currently issued and outstanding. In addition to the voting power held via the Series B Preferred, our officers and directors are also the holders of 57,060,000 shares of the Company’s common stock representing 0.0157% of the issued and outstanding shares of the Company’s common stock. As a result of the issuance of the preferred, the holders total voting percentage, including their common stock, is now 99%. This leaves our outside shareholders with no control over our business and operations, and any investors in our Company should be aware of this risk.

Our management team has limited experience managing a public company, and regulatory compliance may divert its attention from the day-to-day management of our business.

Our management team has limited experience managing a public company, and regulatory compliance may divert its attention from the day-to-day management of our business. Some of the individuals who now constitute our management team have limited experience managing a publicly traded company and limited experience complying with the increasingly complex laws pertaining to public companies. Our management team may not successfully or efficiently manage our continued transition to a public company that will be subject to significant regulatory oversight and reporting obligations under the federal securities laws. In particular, these new obligations will require substantial attention from our senior management and could divert their attention away from the day-to-day management of our business, which could materially and adversely impact our business operations.

Sales concentrations for the year ended December 31, 2020 and 2019.

For the year ended December 31, 2020, one customer accounted for 28% of our business. For the year ended December 31, 2019, three customers accounted for approximately 11% of our business.

A significant part of our business plan depends on marketing of our products and services, which may not be accepted in the marketplace.

Our industry is extremely competitive and we have yet to attain any significant market share. In order to achieve successful operations, we will depend on effective marketing to gain a significantly larger market share. We do not engage independent sales representatives. We do not employ a marketing agency. Employing a greater number of marketing personnel or a marketing agency would require greater financial resources than we currently possess. Furthermore, our ability to attract independent sales representatives may be limited without greater name recognition, an advertising campaign and market penetration. Unless we are able to address these limitations in our marketing capabilities, you may expect our revenues to be limited and we may have difficulty staying in business. And under such circumstances, our stock would not gain in value.

We operate in and plan to expand into extremely competitive environments, which will make it difficult for us to achieve market recognition and revenues.

We operate in an extremely competitive environment and the markets for our products and services are characterized by rapidly changing technologies, frequent new product introductions, short product life cycles and evolving industry standards. Our success depends, in substantial part, on the timely and successful introduction of our new products and services and thereafter upgrades of our products and services to comply with emerging industry standards and to address competing technological and product developments by our competitors. We may focus our resources on technologies that do not become widely accepted, are not timely released or are not commercially viable. In addition, our products may contain defects or errors that are detected only after deployment. If our products are not competitive or do not work properly, our business could suffer and our financial performance could be negatively impacted. You have no assurance that our new products and services, which we intend to be a significant part or our business, will be accepted in the marketplace. If our products and services do not achieve market acceptance, our revenues will be significantly below the level we anticipate.

We are an early-stage company with an unproven business model and our business may not become profitable.

We are an early-stage company with a limited operating history upon which you can evaluate our business. We have very limited historical financial data. As a result of these factors, the revenue and income potential of our business is unproven, and we have only a limited operating history upon which to base an evaluation of our current business and future prospects. Because of our limited operating history and because the health care industry is rapidly evolving, we have limited insight into trends that may emerge and affect our business. We may make errors in predicting and reacting to relevant business trends, which could harm our business. Early-stage companies in new and rapidly evolving markets such as ours frequently encounter risks, uncertainties, and difficulties, including those described in this section. We may not be able to successfully address any or all of these risks. Failure to adequately address such risks could cause our business, financial condition, results of operations and prospects to suffer.

Our revenues are highly susceptible to declines as a result of unfavorable economic conditions.

Economic downturns could affect the hearing aid industry more severely than other industries, and the recovery of the hearing aid industry could lag behind that of the economy generally. In the past, some clients have responded to weakening economic conditions by reducing their purchases of hearing aids in general and marketing budgets specifically, which include discretionary components that are easier to reduce in the short term than other operating expenses. This pattern may recur in the future. A decrease in our revenue could pose a challenge to our cash generation from operations.

Our financial condition could be adversely affected if our available liquidity is insufficient.

If our business is significantly adversely affected by further deterioration in the economic environment or otherwise, it could lead us to seek new or additional sources of liquidity to fund our needs. Currently, for a non-investment-grade company such as ours, the capital markets are challenging, with limited available financing and at higher costs than in recent years. There can be no guarantees that we would be able to access any new sources of liquidity on commercially reasonable terms or at all.

We may lose or fail to attract and retain key employees and management personnel.

Our employees, including creative, research, media and account specialists, and their skills and relationships with clients, are among our most important assets. An important aspect of our competitiveness is our ability to attract and retain key employees and management personnel. Our ability to do so is influenced by a variety of factors, including the compensation we award, and could be adversely affected by our financial or market performance.

We currently have only a small management team and staff, which could limit our ability to effectively seize market opportunities and grow our business.

Our operations are subject to all of the risks inherent in a growing business enterprise, including the likelihood of operating losses. As a smaller company with a limited operating history, our success will depend, among other factors, upon how we manage the problems, expenses, difficulties, complications and delays frequently encountered in connection with the growth of a new business, products and channels of distribution, and current and future development. In addition, as a company with a limited operating history and only a small management team and staff to grow the business and manage the risks inherent in a growing business enterprise, these factors could limit our ability to effectively seize market opportunities and grow.

We are subject to regulations and other governmental scrutiny that could restrict our activities or negatively impact our revenues.

Our marketing sector is subject to government regulation and other governmental action, both domestic and foreign. There has been an increasing tendency on the part of advertisers and consumer groups to challenge advertising through legislation, regulation, the courts or otherwise. For example, challenges have been made in the courts on the grounds that the advertising is false and deceptive or injurious to public welfare. Through the years, there has been a continuing expansion of specific rules, prohibitions, media restrictions, labeling disclosures and warning requirements with respect to the advertising for certain products. Representatives within government bodies, both domestic and foreign, continue to initiate proposals to ban the advertising of specific products and to impose taxes on or deny deductions for advertising, which, if successful, may have an adverse effect on advertising expenditures and consequently our revenues.

We are subject to the periodic reporting requirements of Section 15(d) of the Exchange Act that requires us to incur audit fees and legal fees in connection with the preparation of such reports. These additional accounting, audit, legal, printing, public relations and other costs could reduce or eliminate our ability to earn a profit. We are required to file periodic reports with the SEC pursuant to the Exchange Act and the rules and regulations promulgated thereunder. In order to comply with these requirements, our independent registered public accounting firm will have to review our financial statements on a quarterly basis and audit our financial statements on an annual basis. Moreover, our legal counsel will have to review and assist in the preparation of such reports. The incurrence of such costs constitutes an expense to our operations and thus have a negative effect on our ability to meet our overhead requirements and earn a profit. We are also continually exposed to potential risks resulting from any new requirements under Section 404 of the Sarbanes-Oxley Act of 2002. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported financial information, and the trading price of our common stock, could drop significantly

If we experience significant fluctuations in our rate of anticipated growth and fail to balance our expenses with our revenue forecasts, our results could be harmed.

Due to our evolving business model, the unpredictability of new markets that we intend to enter, and the unpredictability of future general economic and financial market conditions, we may not be able to accurately forecast our rate of growth. We plan our expense levels and investment on estimates of future revenue and future anticipated rate of growth. As a result, we expect that our revenues, operating results and cash flows may fluctuate significantly on a quarterly basis

We may in the future be sued by third parties for alleged infringement of their proprietary rights.

The software and Internet industries are characterized by the existence of a large number of patents, trademarks and copyrights and by frequent litigation based on allegations of infringement or other violations of intellectual property rights. We may receive in the future communications from third parties claiming that we have infringed the intellectual property rights of others. We may in the future be sued by third parties for alleged infringement of their proprietary rights. Our technologies may not be able to withstand any third-party claims against their use. The outcome of any litigation is inherently uncertain. Any intellectual property claims, whether with or without merit, could be time-consuming and expensive to resolve, could divert management attention from executing our business plan and could require us to change our technology, change our business practices and/or pay monetary damages or enter into short- or long-term royalty or licensing agreements which may not be available in the future at the same terms or at all.

We rely on third-party computer hardware and software that may be difficult to replace or which could cause errors or failures of our service.

We will rely on computer hardware purchased or leased and software licensed from third parties in order to offer our proposed service, including database software from Oracle Corporation and an open-source content management system. This hardware and software may not continue to be available at reasonable prices or on commercially reasonable terms, or at all. Any loss of the right to use any of this hardware or software could significantly increase our expenses and otherwise result in delays in the provisioning of our service until equivalent technology is either developed by us, or, if available, is identified, obtained and integrated, which could harm our business. Any errors or defects in third-party hardware or software could result in errors or a failure of our service which could harm our business.

Our business could be adversely affected if our customers are not satisfied with their purchase through us or the implementation and customization services provided by third party Service Providers.

Our business will depend on our ability to satisfy our potential customers. If a customer is not satisfied with the quality of the product or service, the customer's dissatisfaction could damage our ability to obtain additional or future orders from that customer. In addition, potential negative publicity related to our customer relationships, regardless of its accuracy, may further damage our business by affecting our ability to compete for new business with prospective customers.

We are dependent on our CEO and outsourced consultants, and the loss of one or more of these individuals could harm our business and prevent us from implementing our business plan in a timely manner.

Our success depends substantially upon the continued services of our executive officers and other key members of management, particularly our CEO, Matthew Moore. We do not maintain key person life insurance policies on our CEO. The loss of the services of our CEO could seriously harm our business.

Our CEO is also an Officer or a managing member of Moore Family Hearing Company Inc., Moore Holdings, LLC and Value Hearing, LLC, and we have entered into transactions with these entities.

Our future growth may be dependent, in part, on our distribution arrangements directly with retailers and regional retail accounts. If we are unable to establish and maintain these arrangements, our results of operations and financial condition could be adversely affected.

Our future growth may be dependent in part on our distribution arrangements directly with retailers and regional retail accounts. If we are unable to establish and maintain these arrangements, our results of operations and financial condition could be adversely affected. We currently have distribution arrangements with a few regional retail accounts to distribute our products directly through their venues; however, there are several risks associated with this distribution strategy. First, we do not have long-term agreements in place with any of these accounts and thus, the arrangements are terminable at any time by these retailers or us. Accordingly, we may not be able to maintain continuing relationships with any of these national accounts. A decision by any of these retailers, or any other large retail accounts we may obtain, to decrease the amount purchased from us or to cease carrying our products could have a material adverse effect on our reputation, financial condition or results of operations. In addition, we may not be able to establish additional distribution arrangements with other national retailers. In addition, our dependence on large regional retail chains may result in pressure on us to reduce our pricing to them or seek significant product discounts. In general, our margins are lower on our sales to these customers because of these pressures. Any increase in our costs for these retailers to carry our product, reduction in price, or demand for product discounts could have a material adverse effect on our profit margin.

Our ability to grow our business may depend on developing a positive brand reputation and member loyalty.

Establishing and maintaining a positive brand reputation and nurturing member loyalty is critical to attracting new customers. We expect to expend reasonable but limited resources to develop, maintain and enhance our brand in the near future. In addition, nurturing customer loyalty will depend on our ability to provide a high-quality, user experience. If we are unable to maintain and enhance our brand reputation and customer satisfaction, our ability to attract new customers will be harmed.

Investors may lose their entire investment if we fail to reach profitability.

We commenced business in 2006. We have no demonstrable operations record from which you can evaluate the business and its prospects. Our prospects must be considered in light of the risks, uncertainties, expenses and difficulties frequently encountered by companies in their early stages of development. We cannot guarantee that we will be successful in accomplishing our objectives. To date, we have incurred losses and will continue to do so in the foreseeable future. Investors should therefore be aware that they may lose their entire investment in the securities.

We have limited protection of our intellectual property.

Our business prospects do not rely upon company-owned patented technologies. Our business prospects will depend largely on our ability to service and support customers and deliver services and solutions. There can be no assurance that we will be able to adequately protect our trade secrets. In the event competitors independently develop or otherwise obtain access to our know-how, concepts or trade secrets, we may be adversely affected.

Litigation or legal proceedings could expose us to significant liabilities and damage our reputation.

We may become party to litigation claims and legal proceedings. Litigation involves significant risks, uncertainties and costs, including distracting of management’s attention away from our current business operations. We evaluate litigation claims and legal proceedings to assess the likelihood of unfavorable outcomes and to estimate, if possible, the amount of potential losses. Based on these assessments and estimates, we establish reserves and/or disclose the relevant litigation claims or legal proceedings, as appropriate. These assessments and estimates are based on the information available to management at the time and involve a significant amount of management judgment. We caution you that actual outcomes or losses may differ materially from those envisioned by our current assessments and estimates. Our policies and procedures require strict compliance by our employees and agents with all United States and local laws and regulations applicable to our business operations, including those prohibiting improper payments to government officials. Nonetheless, there can be no assurance that our policies and procedures will always ensure full compliance by our employees and agents with all applicable legal requirements. Improper conduct by our employees or agents could damage our reputation in the United States and internationally or lead to litigation or legal proceedings that could result in civil or criminal penalties, including substantial monetary fines, as well as disgorgement of profits.

Our business model is subject to change

We may elect from time to time to make pricing, service, hiring and marketing decisions that could increase our expenses, affect our revenues and impact our financial results. Moreover, because our expense levels in any given quarter are based, in part, on management’s expectations regarding future revenues, if revenues are below expectations, the effect on our operating results may be magnified by our inability to adjust spending in a timely manner to compensate for a shortfall in revenues. The extent to which expenses are not subsequently followed by increased revenues would harm our operating results and could seriously impair our business.

If we do not effectively manage changes in our business, these changes could place a significant strain on our management and operations.

To manage our growth successfully, we must continue to improve and expand our systems and infrastructure in a timely and efficient manner. Our controls, systems, procedures and resources may not be adequate to support a changing and growing company. If our management fails to respond effectively to changes and growth in our business, including acquisitions, this could have a material adverse effect on the Company’s business, financial condition, results of operations and future prospects.

As we attempt to expand our customer base through our marketing efforts, our new customers may use our products differently than our existing customers and, accordingly, our business model may not be as efficient at attracting and retaining new customers.

As we attempt to expand our customer base, our new customers may use our products differently than our existing customers. For example, a greater percentage of new customers may take advantage of the free trial period we offer but ultimately choose to use another form of marketing to reach their constituents. If our new customers are not as loyal as our existing customers, our attrition rate will increase and our customer referrals will decrease, which would have an adverse effect on our results of operations. In addition, as we seek to expand our customer base, we expect to increase our spending on sales and marketing activities in order to attract new customers, which will increase our operating costs. There can be no assurance that these sales and marketing efforts will be successful

U.S. federal legislation entitled Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003 imposes certain obligations on the senders of commercial emails, which could minimize the effectiveness of our email marketing solution, and establishes financial penalties for non-compliance, which could increase the costs of our business.

Part of our marketing plan includes email advertising. U.S. federal legislation entitled Controlling the Assault of Non-Solicited Pornography and Marketing Act of 2003 imposes certain obligations on the senders of commercial emails, which could minimize the effectiveness of our email marketing solution, and establishes financial penalties for non-compliance, which could increase the costs of our business. In December 2003, Congress enacted Controlling the Assault of Non- Solicited Pornography and Marketing Act of 2003, or the CAN-SPAM Act, which establishes certain requirements for commercial email messages and specifies penalties for the transmission of commercial email messages that are intended to deceive the recipient as to source or content. The CAN-SPAM Act, among other things, obligates the sender of commercial emails to provide recipients with the ability to opt out of receiving future emails from the sender. In addition, some states have passed laws regulating commercial email practices that are significantly more punitive and difficult to comply with than the CAN-SPAM Act, particularly Utah and Michigan, which have enacted do-not-email registries listing minors who do not wish to receive unsolicited commercial email that markets certain covered content, such as adult or other harmful products. Some portions of these state laws may not be preempted by the CAN-SPAM Act. The ability of our customers’ constituents to opt out of receiving commercial emails may minimize the effectiveness of our email marketing solution. Moreover, non-compliance with the CAN-SPAM Act carries significant financial penalties. If we were found to be in violation of the CAN-SPAM Act, applicable state laws not preempted by the CAN-SPAM Act, or foreign laws regulating the distribution of commercial email, whether as a result of violations by our customers or if we were deemed to be directly subject to and in violation of these requirements, we could be required to pay penalties, which would adversely affect our financial performance and significantly harm our business. We also may be required to change one or more aspects of the way we operate our business, which could impair our ability to attract and retain customers or increase our operating costs.

Government regulation of the Internet, e-commerce and m-commerce is evolving, and unfavorable changes or failure by us to comply with these laws and regulations could substantially harm our business and results of operations. We are subject to general business regulations and laws as well as regulations and laws specifically governing the Internet, e-commerce and m-commerce in a number of jurisdictions around the world. Existing and future regulations and laws could impede the growth of the Internet, e-commerce, m-commerce or other online services. These regulations and laws may involve taxation, tariffs, privacy and data security, anti-spam, data protection, content, copyrights, distribution, electronic contracts, electronic communications and consumer protection. It is not clear how existing laws and regulations governing issues such as property ownership, sales and other taxes, libel and personal privacy apply to the Internet as the vast majority of these laws and regulations were adopted prior to the advent of the Internet and do not contemplate or address the unique issues raised by the Internet, e- commerce or m-commerce. It is possible that general business regulations and laws, or those specifically governing the Internet, e-commerce or m-commerce may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other rules or our practices. We cannot assure you that our practices have complied, comply or will comply fully with all such laws and regulations. Any failure, or perceived failure, by us to comply with any of these laws or regulations could result in damage to our reputation, a loss in business, and proceedings or actions against us by governmental entities or others. Any such proceeding or action could hurt our reputation, force us to spend significant resources in defense of these proceedings, distract our management, increase our costs of doing business, and cause consumers and retailers to decrease their use of our marketplace, and may result in the imposition of monetary liability. We may also be contractually liable to indemnify and hold harmless third parties from the costs or consequences of noncompliance with any such laws or regulations. In addition, it is possible that governments of one or more countries may seek to censor content available on our websites and mobile applications or may even attempt to completely block access to our marketplace. Adverse legal or regulatory developments could substantially harm our business. In particular, in the event that we are restricted, in whole or in part, from operating in one or more countries, our ability to retain or increase our customer base may be adversely affected and we may not be able to maintain or grow our net revenues as anticipated.

Our business practices with respect to data and consumer protection could give rise to liabilities or reputational harm as a result of governmental regulation, legal requirements or industry standards relating to consumer privacy, data protection and consumer protection. Federal, state and international laws and regulations govern the collection, use, retention, sharing and security of data that we collect. We strive to comply with all applicable laws, regulations, self-regulatory requirements and legal obligations relating to privacy, data protection and consumer protection, including those relating to the use of data for marketing purposes. It is possible, however, that these requirements may be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and may conflict with other rules or our practices. We cannot assure you that our practices have complied, comply, or will comply fully with all such laws, regulations, requirements and obligations. Any failure, or perceived failure, by us to comply with federal, state or international laws or regulations, including laws and regulations regulating privacy, data security, marketing communications or consumer protection, or other policies, self-regulatory requirements or legal obligations could result in harm to our reputation, a loss in business, and proceedings or actions against us by governmental entities, consumers, retailers or others. We may also be contractually liable to indemnify and hold harmless performance marketing networks or other third parties from the costs or consequences of noncompliance with any laws, regulations, self-regulatory requirements or other legal obligations relating to privacy, data protection and consumer protection or any inadvertent or unauthorized use or disclosure of data that we store or handle as part of operating our business. Any such proceeding or action, and any related indemnification obligation, could hurt our reputation, force us to incur significant expenses in defense of these proceedings, distract our management, increase our costs of doing business and cause consumers and retailers to decrease their use of our marketplace, and may result in the imposition of monetary liability.

The Company may lose its status as an Emerging Growth Company.

Under Section 2(a)(19) of the Securities Act of 1933 and Section 3(a)(80) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), an Emerging Growth Company ("EGC") will lose its EGC status upon the earliest of:

•	the last day of the first fiscal year in which the company's annual gross revenues exceed $1 billion;
•	the date on which the company is deemed to be a large accelerated filer (as defined in Rule 12b-2 under the Exchange Act);
•	the date on which the company has, during the previous three-year period, issued more than $1 billion in non-convertible debt; and
•	the last day of the fiscal year in which the fifth anniversary of the company's first sale of equity securities pursuant to an effective registration statement occurs.

Risks Related to Our Common Stock

We have raised capital through the use of convertible debt instruments that causes substantial dilution to our stockholders.

Because of the size of our Company and its status as a “penny stock” as well as the current economy and difficulties of companies our size experience in finding adequate sources of funding, we have been forced to raise capital through the issuance of convertible notes and other debt instruments. These debt instruments carry favorable conversion terms to their holders of up to 35% discounts to the market price of our common stock on conversion and in some cases provide for the immediate sale of our securities into the open market, which will cause dilution to our stockholders. As of December 31, 2020, we had approximately $3,286,270 in convertible debt and potential convertible debt outstanding, with weighted average interest of approximately 8%. The convertible debt is convertible into approximately 4,650,854,286 shares of common stock at December 31, 2020. This convertible debt balance as well as additional convertible debt we incur in the future will cause substantial dilution to our stockholders.

Because we are quoted on the OTCPINK instead of an exchange or national quotation system, our investors may have a tougher time selling their stock or experience negative volatility on the market price of our common stock.

Our common stock is quoted on the OTCPINK. The OTCPINK is often highly illiquid, in part because it does not have a national quotation system by which potential investors can follow the market price of shares except through information received and generated by a limited number of broker-dealers that make markets in particular stocks. There is a greater chance of volatility for securities that are quoted on the OTCQB as compared to a national exchange or quotation system. This volatility may be caused by a variety of factors, including the lack of readily available price quotations, the absence of consistent administrative supervision of bid and ask quotations, lower trading volume, and market conditions. Investors in our common stock may experience high fluctuations in the market price and volume of the trading market for our securities. These fluctuations, when they occur, have a negative effect on the market price for our securities. Accordingly, our stockholders may not be able to realize a fair price from their shares when they determine to sell them or may have to hold them for a substantial period of time until the market for our common stock improves.

Our stock is listed on the OTCPINK, if we fail to remain current on our reporting requirements, we could be removed from the OTCPINK which would limit the ability of broker-dealers to sell our securities in the secondary market.

Companies trading on the OTCPINK, must be reporting issuers under Section 12 of the Securities Exchange Act of 1934, as amended, and must be current in their reports under Section 13, in order to maintain price quotation privileges on the OTCPINK. As a result, the market liquidity for our securities could be severely adversely affected by limiting the ability of broker-dealers to sell our securities and the ability of stockholders to sell their securities in the secondary market. In addition, we may be unable to get relisted on the OTCPINK, which may have an adverse material effect on the Company.

The Possible Sale of Shares of Common Stock by Our Selling Security Holders May Have a Significant Adverse Effect on the Market Price of Our Common Stock.

We have registered 906,000 shares of common stock with the U.S. Securities Exchange Commission. The security holders may sell some or all of their shares at anytime. In the event that the security holders sell some or all of their shares, the price of our common stock could decrease significantly.

Our ability to raise additional capital through the sale of our stock in a private placement may be harmed by these competing re-sales of our common stock by the selling security holders. Potential investors may not be interested in purchasing shares of our common stock if the selling security holders are selling their shares of common stock. The selling of stock by the security holders could be interpreted by potential investors as a lack of confidence in us and our ability to develop a stable market for our stock. The price of our common stock could fall if the selling security holders sell substantial amounts of our common stock. These sales may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem appropriate because the selling security holders may offer to sell their shares of common stock to potential investors for less than we do.

We are an ‘Emerging Growth Company” and we intend to take advantage of reduced disclosure and governance requirements applicable to Emerging Growth Companies, which could result in our stock being less attractive to investors.

We are an "emerging growth company," as defined in the Jumpstart Our Business Startups Act of 2012, which we refer to as the JOBS Act, and we intend to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We cannot predict if investors will find our common stock less attractive because we will rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. We expect to take advantage of these reporting exemptions until we are no longer an emerging growth company, which in certain circumstances could be for up to five years.

The Company’s election to take advantage of the jobs act’s extended accounting transition period may not make its financial statements easily comparable to other companies.

Pursuant to the JOBS Act of 2012, as an emerging growth company the Company can elect to take advantage of the extended transition period for any new or revised accounting standards that may be issued by the Public Company Accounting Oversight Board ("PCAOB") or the Securities & Exchange Commission ("SEC"). The Company has elected take advantage of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the standard on the private company timeframe. This may make comparison of the Company's financial statements with any other public company which is not either an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible as possible different or revised standards may be used.

The Jobs Act will also allow the Company to postpone the date by which it must comply with certain laws and regulations intended to protect investors and reduce the amount of information provided in reports filed with the

The JOBS Act is intended to reduce the regulatory burden on “emerging growth companies. The Company meets the definition of an emerging growth company and so long as it qualifies as an “emerging growth company,” it will, among other things:

•	be exempt from the provisions of Section 404(b) of the Sarbanes-Oxley Act requiring that its independent registered public accounting firm provide an attestation report on the effectiveness of its internal control over financial reporting.

•	be exempt from the “say on pay” provisions (requiring a non-binding shareholder vote to approve compensation of certain executive officers) and the “say on golden parachute” provisions (requiring a non-binding shareholder vote to approve golden parachute arrangements for certain executive officers in connection with mergers and certain other business combinations) of the Dodd-Frank Act and certain disclosure requirements of the Dodd-Frank Act relating to compensation of its chief executive officer;

•	be permitted to omit the detailed compensation discussion and analysis from proxy statements and reports filed under the Securities Exchange Act of 1934 and instead provide a reduced level of disclosure concerning executive compensation; and

•	be exempt from any rules that may be adopted by the Public Company Accounting Oversight Board requiring mandatory audit firm rotation or a supplement to the auditor’s report on the financial statements

The Company currently intends to take advantage of some or all of the reduced regulatory and reporting requirements that will be available to it so long as it qualifies as an “emerging growth company”.

As long as the Company qualifies as an Emerging Growth Company, the Company’s independent registered public accounting firm will not be required to attest to the effectiveness of the company’s internal control over financial reporting.

Because the Company has elected to take advantage of the extended time periods for compliance with new or revised accounting standards provided for under Section 102(b) of the JOBS Act, among other things, this means that the Company's independent registered public accounting firm will not be required to provide an attestation report on the effectiveness of the Company's internal control over financial reporting so long as it qualifies as an emerging growth company, which may increase the risk that weaknesses or deficiencies in the internal control over financial reporting go undetected. Likewise, so long as it qualifies as an emerging growth company, the Company may elect not to provide certain information, including certain financial information and certain information regarding compensation of executive officers that would otherwise have been required to provide in filings with the SEC, which may make it more difficult for investors and securities analysts to evaluate the Company. As a result, investor confidence in the Company and the market price of its common stock may be adversely affected.

The Penny Stock Rules Could Restrict the Ability of Broker-Dealers to Sell Our Shares.

The SEC has adopted penny stock regulations which apply to securities traded over-the-counter. These regulations generally define penny stock to be any equity security that has a market price of less than $5.00 per share or an equity security of an issuer with net tangible assets of less than $5,000,000 as indicated in audited financial statements, if the corporation has been in continuous operations for less than three years. Subject to certain limited exceptions, the rules for any transaction involving a penny stock require the delivery, prior to the transaction, of a risk disclosure document prepared by the SEC that contains certain information describing the nature and level of risk associated with investments in the penny stock market. The broker-dealer also must disclose the commissions payable to both the broker-dealer and the registered representative and current quotations for the securities. Monthly account statements must be sent by the broker- dealer disclosing the estimated market value of each penny stock held in the account or indicating that the estimated market value cannot be determined because of the unavailability of firm quotes. In addition, the rules impose additional sales practice requirements on broker-dealers who sell such securities to persons other than established customers and institutional accredited investors (generally institutions with assets in excess of $5,000,000). These practices require that, prior to the purchase, the broker-dealer determined that transactions in penny stocks were suitable for the purchaser and obtained the purchaser’s written consent to the transaction. If a market for our common stock does develop and our shares trade below $5.00 per share, it will be a penny stock. Consequently, the penny stock rules will likely restrict the ability of broker-dealers to sell our shares and will likely affect the ability of purchasers in the offering to sell our shares in the secondary market. Trading in our common stock will be subject to the “penny stock” rules. Due to the thinly traded market of these shares investors are at a much higher risk to lose all or part of their investment. Not only are these shares thinly traded but they are subject to higher fluctuations in price due to the instability of earnings of these smaller companies. As a result of the lack of a highly traded market in our shares investors are at risk of a lack of brokers who may be willing to trade in these shares.

We do not expect to pay dividends in the future; any return on investment may be limited to the value of our common stock.

We do not currently anticipate paying cash dividends in the foreseeable future. The payment of dividends on our common stock will depend on earnings, financial condition and other business and economic factors affecting it at such time as the board of directors may consider relevant. Our current intention is to apply net earnings, if any, in the foreseeable future to increasing our capital base and development and marketing efforts. There can be no assurance that the Company will ever have sufficient earnings to declare and pay dividends to the holders of our common stock, and in any event, a decision to declare and pay dividends is at the sole discretion of our board of directors. If we do not pay dividends, our common stock may be less valuable because a return on your investment will only occur if its stock price appreciates.

The market price of our common stock may be volatile and may decline in value.

The market price of our common stock has been and will likely continue to be highly volatile, as is the stock market in general, and the market for OTC Marketplace quoted stocks, in particular. Some of the factors that may materially affect the market price of our common stock are beyond our control, such as changes in financial estimates by industry and securities analysts, conditions or trends in the industry in which we operate or sales of our common stock. These factors may materially adversely affect the market price of our common stock, regardless of our performance. In addition, the public stock markets have experienced extreme price and trading volume volatility. This volatility has significantly affected the market prices of securities of many companies for reasons frequently unrelated to the operating performance of the specific companies. These broad market fluctuations may adversely affect the market price of our common stock.

Our stockholders may experience significant dilution if future equity offerings are used to fund operations or acquire complementary businesses.

If our future operations or acquisitions are financed through the issuance of equity securities, our stockholders could experience significant dilution. In addition, securities issued in connection with future financing activities or potential acquisitions may have rights and preferences senior to the rights and preferences of our common stock.

Our current management can exert significant influence over us and make decisions that are not in the best interests of all stockholders.

Our executive officers and directors (the Moores) beneficially own as a group approximately 91% of our outstanding voting shares, including our Series B Preferred Stock. As a result, these stockholders will be able to assert significant influence over all matters requiring stockholder approval, including the election and removal of directors and any change in control. In particular, this concentration of ownership of our outstanding shares of common stock could have the effect of delaying or preventing a change in control, or otherwise discouraging or preventing a potential acquirer from attempting to obtain control. This, in turn, could have a negative effect on the market price of our common stock. It could also prevent our stockholders from realizing a premium over the market prices for their shares of common stock. Moreover, the interests of the owners of this concentration of ownership may not always coincide with our interests or the interests of other stockholders and, accordingly, could cause us to enter into transactions or agreements that we would not otherwise consider.

We could issue additional “blank check” preferred stock without stockholder approval with the effect of diluting then current stockholder interests and impairing their voting rights, and provisions in our charter documents and under Nevada law could discourage a takeover that stockholders may consider favorable.

Our certificate of incorporation, as amended, provides that we may authorize and issue up to 25,000,000 shares of “blank check” preferred stock with designations, rights, and preferences as may be determined from time to time by our Board. Our Board has issued 900,000 of Series B Preferred, and is empowered, without stockholder approval, to issue one or more series of preferred stock with dividend, liquidation, conversion, voting, or other rights, which could dilute the interest of or impair the voting power of our holders of Common Stock. The issuance of a series of preferred stock could be used as a method of discouraging, delaying, or preventing a change in control. For example, it would be possible for our Board to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of our Company.

Investors who purchase shares of our common stock should be aware of the possibility of a total loss of their investment.

An investment in our common stock involves a substantial degree of risk. Before making an investment decision, you should give careful consideration to the risk factors described in this section in addition to the other information contained herein. The risk factors described herein, however, may not reflect all of the risks associated with our business or an investment in our common stock. You should invest in our Company only if you can afford to lose your entire investment.

The Financial Industry Regulatory Authority, or FINRA, sales practice requirements may also limit a stockholder's ability to buy and sell our stock.

In addition to the Penny Stock Rules described above, FINRA has adopted rules that require that in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative low-priced securities to their non- institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer's financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for at least some customers. FINRA requirements make it more difficult for broker-dealers to recommend that their customers buy our common stock, which may limit your ability to buy and sell our stock and have an adverse effect on the market for our shares.

A significant amount of our issued and outstanding shares of common stock are restricted securities and may not be freely resold to the public. When the restriction on any or all of these shares is lifted, and the shares are sold in the open market, the price of our common stock could be adversely affected.

A significant amount of our issued and outstanding shares of common stock are "restricted securities" as defined under Rule 144 promulgated under the Securities Act of 1933, as amended, and may only be sold pursuant to an effective registration statement or an exemption from registration, if available. Although Rule 144 may not be immediately available to permit resale of such shares, once available, and given the number of shares that would no longer be restricted, sales of shares by our shareholders, whether pursuant to Rule 144 or otherwise, could have an immediate negative effect upon the price of our common stock.

ITEM 1B. UNRESOLVED STAFF COMMENTS

Not applicable to a smaller reporting company.

ITEM 2. DESCRIPTION OF PROPERTY

Leases

Office

Space

On June 14, 2017, the company entered into a five-year lease with LLC1 for approximately 6,944 square feet and a monthly rent of $12,000.

Hearing Aid Retail Clinics

On June 14, 2017, the company entered into a five-year lease with LLC1 for approximately 6,944 square feet and a monthly rent of $12,000 with a related party (Note 7). Upon adoption of ASC 842, the Company recognized $434,504 of right-to-use assets as operating leases and operating lease obligations.

On September 10, 2018, pursuant to the Amos Audiology acquisition, the Company assumed a lease dated December 1, 2017, and expiring April 30, 2023, in Walnut Creek, California. Lease payments in the first year of the lease are $3, 988 per month and increase by 3% on December 1 each new lease year. As of December 31, 2018, the Company was in arrears of $25,182 (including late fees) in lease payments and has agreed with the landlord to pay the arrears in seven monthly payments of $3,597 in addition to the monthly lease payments for January 2019 through July 2019. Settlement fees were fully paid during the year ending December 31, 2019.

On October 15, 2018, the Company entered into a lease to operate a retail hearing aid clinic in Roseville, California expiring December 31, 2023. Initial lease payments of $3,102 began on January 1, 2019 and increase by 3% on January 1 each new lease year. Upon adoption of ASC 842, the Company recognized $160,623 of right-to-use assets as operating leases and operating lease obligations. The Company abandoned the lease location in November of 2020, therefore, a ROU asset loss was recognized in the amount of $106,419 during year ending December 31, 2020. No changes to operating lease liability have been made until the settlement has been reached.

On November 18, 2019, the Company entered into a lease to operate a retail hearing aid clinic in Walnut Creek, expiring in October of 2022. Initial lease payments of $3,930 began on December 1, 2019 and increase by 3% on December 1 each new lease year. Upon adoption of ASC 842, the Company recognized $129,281 of right-to-use assets as operating leases and operating lease obligations. The Company abandoned the lease location in April of 2021.

On December 1, 2018, the Company entered into a lease to operate a retail hearing aid clinic in Sacramento, California expiring March 31, 2024. Initial lease payments of $3,002 began on April 1, 2019, and increase by 3.33% on April 1, 2020, and 2021, and by 3% on April 1, 2022. Upon adoption of ASC 842, the Company recognized $149,507 of right-to-use assets as operating leases and operating lease obligations. The Company abandoned the lease location in November of 2020, therefore, a ROU asset loss was recognized in the amount of $102,312 during year ending December 31, 2020. No changes to operating lease liability have been made until the settlement has been reached. Subsequent to year ending December 31, 2020, the Company reached the settlement where the Company agreed to make either one time payment of $44,000 or make fourteen monthly payments of $3,220.

On February 1, 2019, the Company entered into a lease to operate a retail hearing aid clinic in Elk Grove, California expiring January 31, 2024. Initial lease payments of $2,307 began on February 1, 2019, and increase by an average of 2.6% on February 1, each new lease year. Upon adoption of ASC 842, the Company recognized $116,153 of right-to-use assets as operating leases and operating lease obligations. The Company terminated the lease in March of 2021 where the Company agreed to pay $23,911 in order to settle the lease.

On May 31, 2019, the Company entered into a lease to operate a retail hearing aid clinic in Greenhaven, California expiring June 30, 2022. Initial lease payments of $1,450 began on July 1, 2019, and increase by 5% on July 1, each new lease year. Upon adoption of ASC 842, the Company recognized $48,512 of right-to-use assets as operating leases and operating lease obligations. The Company terminated the lease in November of 2020, therefore, a ROU asset loss was recognized in the amount of $27,041, during year ending December 31, 2020. No changes to operating lease liability have been made until the settlement has been reached. Subsequent to year ending December 31, 2021, the Company made a final payout of $6,000, upon which the lease was settled.

On April 15, 2019, the Company entered into a lease to operate a retail hearing aid clinic in Pleasanton, California expiring April of 2024. Initial lease payments of $3,551 began on May 1, 2019 and increase by 3% on May 1 each new lease year. Upon adoption of ASC 842, the Company recognized $185,068 of right-to-use assets as operating leases and operating lease obligations. The Company abandoned the lease location in December of 2019, therefore, a ROU asset loss was recognized in the amount of $153,589 during year ending December 31, 2019. No changes to operating lease liability have been made until the settlement has been reached.

On February 1, 2019, the Company entered into a lease to operate a retail hearing aid clinic in Fremont, California expiring February 28, 2021. Initial lease payments of $2,019 began on March 1, 2019 and increases by 3% on March 1, 2020. The Company terminated the lease in 2019 and agreed to make a payment of $4,038 in order to settle the lease.

On June 1, 2019, the Company entered into a lease to operate a retail hearing aid clinic in Hayward, California expiring June of 2021. Initial lease payments of $1,816 began on June 1, 2019 and increase by 3% on June 1 each new lease year. Upon adoption of ASC 842, the Company recognized $34,486 of right-to-use assets as operating leases and operating lease obligations. The Company abandoned the lease location in December of 2019, therefore, a ROU asset loss was recognized in the amount of $14,348 during year ending December 31, 2019. No changes to operating lease liability have been made until the settlement has been reached.

ITEM 3. LEGAL PROCEEDINGS.

From time to time, claims are made against us in the ordinary course of business, which could result in litigation. Claims and associated litigation are subject to inherent uncertainties and unfavorable outcomes could occur, such as monetary damages, fines, penalties or injunctions prohibiting us from selling one or more products or engaging in other activities. The occurrence of an unfavorable outcome in any specific period could have a material adverse effect on our results of operations for that period or future periods.

However, as of the date of this report, management believes the outcome of currently identified potential claims and lawsuits will not have a material adverse effect on our financial condition or results of operations.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

PART II

ITEM 5. MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

The Company’s common stock began trading on February 14, 2017, on the over-the-counter market, and quoted on the OTCQB tier of the OTC Markets Group Inc. under the symbol “INND.”

(a)

Market Information

The following table sets forth, for the periods indicated the high and low bid quotations for our common stock. These quotations represent inter-dealer quotations, without adjustment for retail markup, markdown, or commission and may not represent actual transactions.

Period		High		Low
Fiscal Year 2020
	First Quarter (January 1, 2020 – March 31, 2020)	$	0.0289	$	0.0013
	Second Quarter (April 1, 2020 – June 30, 2020)	$	0.0027	$	0.0001
	Third Quarter (July 1, 2020 – September 30, 2020)	$	0.0001	$	0.0001
	Fourth Quarter (October 1, 2020 – December 31, 2020)	$	0.0002	$	0.0001

Fiscal Year 2019
First Quarter (January 1, 2019 – March 31, 2019)	$	0.39	$	0.01
Second Quarter (April 1, 2019 – June 30, 2019)	$	0.09	$	0.02
Third Quarter (July 1, 2019 - September 30, 2019)	$	0.09	$	0.01
Fourth Quarter (October 1, 2019 – December 31, 2019)	$	0.02	$	.001

(a)

Holders

The number of record holders of our common stock as of August 5, 2022 was approximately 120 This excludes shareholders who hold their stock in street name. The Company estimates that there are over 1,300 stockholders who hold their shares of common stock in street name.

(b)

Dividends

The Company did not declare any cash dividends for the years ended December 31, 2020, and 2019. Our Board of Directors does not intend to distribute any cash dividends in the near future. The declaration, payment and amount of any future dividends will be made at the discretion of the Board of Directors, and will depend upon, among other things, the results of our operations, cash flows and financial condition, operating and capital requirements, and other factors as the Board of Directors considers relevant. There is no assurance that future dividends will be paid, and if dividends are paid, there is no assurance with respect to the amount of any such dividend.

(c)

Securities authorized for issuance under equity compensation plan s

None

Recent Sales of Unregistered Equity Securities

During the year ending December 31, 2019, the Company issued 12,576,313 shares of common stock as part of compensation for services for a total value of $440,666, based on the market price of the common stock on the date the Company agreed to issue the shares.

During the year ending December 31, 2019, the Company issued 209,116,478 shares of common stock for partial conversion of principal in the amount of $1,082,858 and accrued interest in the amount of $68,383.

During the year ending December 31, 2019, Company’s management made a contribution of $12,048. No shares have been issued.

During the year ending December 31, 2020, the Company issued 3,286,303,906 shares of common stock for partial conversion of principal in the amount of $415,964 and accrued interest in the amount of $44,965.

ITEM 6. SELECTED FINANCIAL DATA

Not applicable to a smaller reporting company.

ITEM 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following is management’s discussion and analysis of certain significant factors that have affected our financial position and operating results during the periods included in the accompanying consolidated financial statements, as well as information relating to the plans of our current management. This report includes forward-looking statements. Generally, the words “believes,” “anticipates,” “may,” “will,” “should,” “expect,” “intend,” “estimate,” “continue,” and similar expressions or the negative thereof or comparable terminology are intended to identify forward-looking statements. Such statements are subject to certain risks and uncertainties, including the matters set forth in this report or other reports or documents we file with the Securities and Exchange Commission from time to time, which could cause actual results or outcomes to differ materially from those projected. Some of our risks and uncertainties are included in the Risk Factors section of this Report, as well as, other reports that we may file from time to time. Undue reliance should not be placed on these forward-looking statements which speak only as of the date hereof. We undertake no obligation to update these forward-looking statements.

The independent auditors’ reports on our financial statements for the years ended December 31, 2020 and 2019 includes a “going concern” explanatory paragraph that describes substantial doubt about our ability to continue as a going concern. Management’s plans in regard to the factors prompting the explanatory paragraph are discussed below and also in Note 4 to the consolidated financial statements filed herein.

While our financial statements are presented on the basis that we are a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business over a reasonable length of time, our auditors have raised a substantial doubt about our ability to continue as a going concern.

Results of Operations

For the year ended December 31, 2020 compared to the year ended December 31, 2019

Revenues

Revenues for the year ended December 31, 2020 were $166,111 compared to $847,109 for the year ended December 31, 2019. The revenue decrease was primarily due to closing of many retail locations due to COVID-19 (Note 14). For the year ended December 31, 2020, a related customer accounted for 0% of our revenues compared to 5% for the year ended December 31, 2019. During the year ended December 31, 2020, one customer accounted for 28% of total revenue.

Online sales

Beginning in the second quarter of 2018, the Company began to market a line of PSAPs and during the third quarter of 2018, expanded their line of products to include FDA registered hearing aid devices. The Company has introduced the products through new marketing campaigns, to bring awareness to the products, which resulted in increase in sales in 2019.

Retail clinic sales

Retail clinic sales significantly decreased in 2020 as a number of retail locations were closed due to COVID-19. As a result, the Company experienced a negative impact to its operating results.

Cost of sales

The Company records the costs of designing, producing, printing and mailing advertisements for our client’s direct mail marketing campaigns in cost of sales in the month of the mailing as well as the licensing of telemarketing software and records cost of sales on products sold online or it its retail locations, when shipped and delivered to the customer, respectively. Cost of sales for the year ended December 31, 2020 was $68,768 compared to $496,736 for the year ended December 31, 2019.

Operating Expenses

Operating expenses were $1,326,587, respectively, for the year ended December 31, 2020, compared to $4,095,200 for the year ended December 31, 2019. The decrease in expenses in the current periods was as follows:

	Year ended December 31,
Description	2020		2019
Compensation and benefits	$	661,840	$	1,575,395
Advertising and promotion		19,762		485,406
Professional fees		114,476		763,157
Rent, including related party		322,879		424,613
Investor relations		14,796		193,696
Depreciation and Amortization expense		123,646		150,024
Other general and administrative		69,188		502,908
	$	1,326,587	$	4,095,200

Compensation and benefits decreased in the current period due to overall decrease in operations due to COVID-19.

Professional fees, for the year ended December 31, 2020 were $114,476 compared to $763,157 for the year ended December 31, 2019. Professional fees, consisted of:

	Year ended December 31,
Description	2020		2019
Accounting and auditing fees	$	45,383	$	100,747
Legal fees		3,228		10,362
Consulting		65,865		652,048
Total	$	114,476	$	763,157

Rent, including related party, decreased for the year ended December 31, 2020, compared to the year ended December 31, 2019 as a result of termination of a number of retail locations.

General and administrative costs were $69,188 for the year ended December 31, 2020, compared to $502,908 for the year ended December 31, 2019. Office and payroll expenses include telephone, office supplies, payroll processing costs and computer and internet costs. Investor relations costs include web hosting on our website, investor presentations and meetings as well as press releases and consultants.

Other income (expense), net

Other expense, net was $3,724,448 for the year ended December 31, 2020, compared to $4,179,513 for the year ended December 31, 2019. Derivative expenses of $2,289,869 and $3,602,512, including amortization of debt discounts as of December 31, 2020 and 2019, respectively, decreased due to less new convertible notes during 2020. Interest expense of $489,123 and $386,303 for the years ended December 31, 2020 and 2019, respectively, increased due to new loans. The 2020 period included a loss of $775,000 recorded on intangibles as the Company determined that it was unable to substantiate the actual fair value of the technology that was acquired so has chosen to impair the full amount. Company recorded a loss on lease termination of $201,283 and $146,337 during the years ended December 31, 2020 and 2019 due to canceling a number of leases (Note 11).

Net loss

Net loss for the year ended December 31,2020 was $4,953,692 compared to $7,924,339 for the year ended December 31, 2019. The decrease in the loss was mainly due to the decrease in operations due to COVID-19.

Capital Resources and Liquidity

Liquidity is the ability of an enterprise to generate adequate amounts of cash to meet its needs to pay ongoing obligations. As of December 31, 2020, we had cash of $3,349, a decrease of $1,110, from $4,459 as of December 31, 2019. As of December 31, 2020, we had current liabilities of $10,418,996 (including derivative liabilities of $4,046,401) compared to current assets of $23,449 which resulted in working capital deficit of 10,395,547. The current liabilities are comprised of accounts payable, accrued expenses, notes payable, convertible notes payable and derivative liabilities.

Our ability to operate over the next 12 months, is contingent upon continuing to realize sales revenue sufficient to fund our ongoing expenses. If we are unable to sustain our ongoing operations through sales revenue, we intend to fund operations through debt and/or equity financing arrangements, which may be insufficient to fund our working capital, or other cash requirements. There can be no assurance that such additional financing will be available to us on acceptable terms, or at all. Our ability to operate beyond December 31, 2021, is contingent upon continuing to realize sales revenue sufficient to fund our ongoing expenses. If we are unable to sustain our ongoing operations through sales revenue, we intend to fund operations through debt and/or equity financing arrangements, which may be insufficient to fund our working capital, or other cash requirements. Since December 31, 2020, we have received $8,300,686, from the issuance of $6,550,957 of convertible notes, $650,000 from sale of common stock and approximately $1,099,729 from the sales of hearing aid products. We do not have any formal commitments or arrangements for the sales of stock or the advancement or loan of funds at this time. There can be no assurance that such additional financing will be available to us on acceptable terms, or at all.

Operating Activities

Cash used in operating activities was $523,534 for the year ended December 31, 2020 compared to $2,925,937 for the year ended December 31, 2019. For the year ended December 31, 2020, the cash used in operations was a result of the net loss of $4,953,692, loss recognized on ROU asset of $204,416, and increases in assets of $134,730, offset by increases in liabilities of $995,017 and the non- cash expense items of depreciation and amortization of $1,172,111 derivative loss of $1,066,904, loss on intangibles impairment of $775,000 and gain on equity investment of $30,646.

The Company used $2,925,941 cash in operating activities for the year ended December 31, 2019. For the year ended December 31, 2019, the cash used in operations was a result of the net loss of $7,924,339, offset by the changes in the current assets of $599,240 and changes in liabilities of $77,502, respectively, as well loss recognized on ROU asset of $167,938, and the non- cash expense items of depreciation and amortization of $2,850,033, derivative loss of $647,633, stock based compensation of $440,667 and loss on equity investment of $15,083.

Investing Activities

Cash used in investing activities was $7,272 for the year ended December 31, 2020, and was comprised of purchase of equipment in the amount of $7,272. Cash used in investing activities was $59,175 for the year ended December 31, 2019. Such investing activities were comprised of purchase of equipment in the amount of $49,614 and $9,561 change in equity investment.

Financing Activities

For the year ended December 31, 2020, the Company has received proceeds, net of repayments made, of $269,611 from the issuance of convertible notes, and cash proceeds of $262,445 from a Paycheck Protection Program loan. For the year ended December 31, 2020, the Company had changes in bank overdraft in the amount of $2,360. For the year ended December 31, 2019, the Company received proceeds, net of repayments, of $2,854,250 from the issuance of convertible notes, proceeds, net of repayments, of $32,820 from notes payable and a related party contribution in the amount of $12,048. For the year ended December 31, 2020, the Company had changes in bank overdraft in the amount of $2,631.

OFF BALANCE SHEET ARRANGEMENTS

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition or results of operations.

Critical Accounting Policies

Basis of presentation

The accompanying consolidated financial statements are prepared in accordance with Generally Accepted Accounting Principles in the United States of America ("US GAAP"). The consolidated financial statements of the Company include the consolidated accounts of InnerScope and its’ wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation.

Emerging Growth Companies

The Company qualifies as an “emerging growth company” under the 2012 JOBS Act. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. As an emerging growth company, the Company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. The Company has elected to take advantage of the benefits of this extended transition period.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported period. Significant estimates relied upon in preparing these financial statements include collectability of accounts receivable, accounts receivable from a related party and notes receivable from an officer, inventory allowances for slow moving or obsolete inventory and the allocation of our CEO’s compensation to the Company. Actual results could differ from those estimates.

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. Cash and cash equivalent balances may, at certain times, exceed federally insured limits. If the amount of a deposit at any time exceeds the federally insured amount at a bank, the uninsured portion of the deposit could be lost, in whole or in part, if the bank were to fail.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash due to the financial position of the depository institution in which those deposits are held.

Revenue Recognition

The Company has adopted ASU 2014-09, as amended effective January 1, 2018, and determined that there was no significant impact on its revenue recognition. The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle. The Company recognizes revenue under ASC 606 Revenue from Contracts with Customers. The Company’s revenue recognition policy standards include the following elements:

Identify the contract with a customer

II.

Identify the performance obligations in the contract

III.

Determine the transaction price

IV.

Allocate the transaction price to the performance obligations in the contract

Recognize revenue when (or as) the entity satisfies a performance obligation.

The Company’s contracts with customers are generally on a purchase order basis and represent obligations that are satisfied at a point in time as defined in the new guidance. Accordingly, revenue for each sale is recognized when each sale is complete, which is when the customer receives the goods and any costs incurred before this point in time, are recorded as assets to be expensed during the period the related revenue is recognized. The Company accepts prepayments on hearing aids and records the amount received as customer deposits on its’ balance sheet. When the Company delivers the hearing aid to the customer, revenue is recognized as well as the corresponding cost of sales. All goods are delivered to the customer using public carriers. Company bears any loss during transit. As of December 31, 2020, the Company had received $10,925 of customer deposits, that will be recognized after December 31, 2021, when the hearing aids are delivered to the customer.

Deferred Revenue

The Company records deferred revenues from the Consulting Agreement when cash has been received, but the related services have not been provided. Deferred revenue will be recognized when the services are provided, and the terms of the agreements have been fulfilled.

Advertising and Marketing Expenses

The Company expenses advertising and marketing costs as incurred. For the years ended December 31, 2020 and 2019, advertising and marketing expenses were $19,762 and $485,407, respectively.

Investment in Undivided Interest in Real Estate

The Company accounts for its’ investment in undivided interest in real estate using the equity method, as the Company is severally liable only for the indebtedness incurred with its interest in the property. The Company includes its allocated portion of net income or loss in Other income (expense) in its Statement of Operations, with the offset to the equity investment account on the balance sheet. For the years ended December 31, 2020 and 2019, the Company recognized a gain of $30,646 and $15,083, respectively. As of December 31, 2020 and 2019, the carrying value the carrying value of our investment in undivided interest in real estate was $1,227,733 and $1,210,526, respectively.

Fair Value of Financial Instruments

The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

The following are the hierarchical levels of inputs to measure fair value:

•

Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.

•

Level 2 - Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.

•

Level 3 - Unobservable inputs reflecting the Company's assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

The following table represents the Company’s financial instruments that are measured at fair value on a recurring basis as of December 31, 2020, and 2019, for each fair value hierarchy level:

	December 31, 2019
	Level 1		Level 2		Level 3		Total
Derivative liabilities	$	—	$	—	$	3,515,055	$	3,515,055
	$	—	$	—	$	3,515,055	$	3,515,055

		December 31, 2020
		Level 1		Level 2		Level 3		Total
Derivative liabilities	$	—	$	—	$	4,046,401	$	4,046,401
	$	—	$	—	$	4,046,401	$	4,046,401

Income Taxes

The Company accounts for income taxes in accordance with ASC 740-10, Income Taxes. Deferred tax assets and liabilities are recognized to reflect the estimated future tax effects, calculated at the tax rate expected to be in effect at the time of realization. A valuation allowance related to a deferred tax asset is recorded when it is more likely than not that some portion of the deferred tax asset will not be realized. Deferred tax assets and liabilities are adjusted for the effects of the changes in tax laws and rates of the date of enactment.

ASC 740-10 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. Interest and penalties are classified as a component of interest and other expenses. To date, the Company has not been assessed, nor paid, any interest or penalties.

Uncertain tax positions are measured and recorded by establishing a threshold for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Only tax positions meeting the more-likely-than-not recognition threshold at the effective date may be recognized or continue to be recognized.

Earnings (loss) Per Share

The Company reports earnings (loss) per share in accordance with ASC 260, "Earnings per Share." Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of December 31, 2020, and 2019, the Company’s outstanding convertible debt is convertible into 4,650,854,286 and 155,226,039, respectively, shares of common stock, respectively, subject to adjustment based on changes in the Company’s stock price. This amount is not included in the computation of dilutive loss per share because their impact is antidilutive.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Not required for smaller reporting companies.

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

See Index to Financial Statements and Financial Statement Schedules appearing on pages F-1 to F-12 of this annual report on Form 10-K.

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE.

None.

ITEM 9A. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

A review and evaluation was performed by the Company’s management, including the Company’s Chief Executive Officer (the “CEO”) and Chief Financial Officer (the “CFO”), as of the end of the period covered by this annual report on Form 10-K, of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of the end of the period covered by this annual report. Based on that review and evaluation, the CEO and CFO have concluded that as of December 31, 2020, disclosure controls and procedures were not effective at ensuring that the material information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported as required in the application of SEC rules and forms.

Management’s Report on Internal Controls over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is de fined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Internal control over financial reporting is a set of processes designed by, or under the supervision of, a company’s principal executive and principal financial officers, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP and includes those policies and procedures that:

•

Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect our transactions and disposition of our assets;

•

Provide reasonable assurance our transactions are recorded as necessary to permit preparation of our financial statements in accordance with GAAP, and that receipts and expenditures are being made only in accordance with authorizations of our management and directors; and

•

Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. It should be noted that any system of internal control, however well designed and operated, can provide only reasonable, and not absolute, assurance that the objectives of the system will be met. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Our CEO and CFO have evaluated the effectiveness of our internal control over financial reporting as described in Exchange Act Rules 13a-15(e) and 15d-15(e) as of the end of the period covered by this report based upon criteria established in “Internal Control-Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). As a result of this evaluation, we concluded that our internal control over financial reporting was not effective as of December 31, 2020, as described below.

We assessed the effectiveness of the Company’s internal control over financial reporting as of evaluation date and identified the following material weaknesses:

Insufficient Resources: We have an inadequate number of personnel with requisite expertise in the key functional areas of finance and accounting.

Inadequate Segregation of Duties : We have an inadequate number of personnel to properly implement control procedures.

Lack of Audit Committee: We do not have a functioning audit committee, resulting in lack of independent oversight in the establishment and monitoring of required internal controls and procedures.

We are committed to improving the internal controls and will (1) consider to use third party specialists to address shortfalls in staffing and to assist us with accounting and finance responsibilities, (2) increase the frequency of independent reconciliations of significant accounts which will mitigate the lack of segregation of duties until there are sufficient personnel and (3) may consider appointing additional outside directors and audit committee members in the future.

We have discussed the material weakness noted above with our independent registered public accounting firm. Due to the nature of these material weaknesses, there is a more than remote likelihood that misstatements which could be material to the annual or interim financial statements could occur that would not be prevented or detected.

This Annual Report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our independent registered public accounting firm pursuant to the rules of the SEC that permit us to provide only management’s report in this annual report.

Changes in Internal Control over Financial Reporting

There have been no changes in the Company’s internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

ITEM 9B. OTHER INFORMATION

None.

PART III

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

Identification of directors and executive officers.

The names and ages of our directors and executive officers are set forth below. Also included is their principal occupation(s). Our By-Laws provide for three directors. All directors are elected annually by the stockholders to serve until the next annual meeting of the stockholders and until their successors are duly elected and qualified.

Name	Age	Position	Director Since
Mark Moore	59	Chairman	June 18, 2012
Kim Moore	65	Treasurer and Director	June 18, 2012
Matthew Moore	35	CEO and Director	June 18, 2012

Mark Moore, Chairman

Mr. Moore has 37 years in hearing aid dispensing, practice management, private label brand management and marketing, Mr. Moore brings a wealth of experience and perspective to our field. Mr. Moore’s expertise in not only running a successful multi-office retail dispensing practice, but also developing time-tested proven new marketing and advertising strategies over the past 25 years has made him one of the most sought-after experts in the hearing aid industry. He has personally helped over 10,000 people hear better with hearing amplification.

Mr. Moore previously was a columnist for Advanced for Audiologists as well as Senior Publications throughout Northern California. Mr. Moorehas also developed patented and patent-pending products in the areas of Nutritional Supplements for hearing related issues, Aural Rehabilitation programs, and Low-Level Laser Therapy for Tinnitus and Sensorineural hearing loss.

Mr. Moore is a graduate of San Diego Golf Academy with a business degree. He and his wife, Kim, who is also a licensed dispenser, live in Granite Bay, CA.

Kim Moore, Treasurer and Director

Mrs. Moore has over 50 years of experience in the Hearing Aid Industry. She literally grew up in the industry helping her father, Marvin Posey, develop and maintain his hearing aid practice, Posey’s Hearing Aid Center, in Central Valley, California.

Mrs. Moore started working for her father at age eight, when she would help stuff direct mail pieces for an upcoming marketing campaign. She learned from her father that no potential customer walks through the door unless you advertise and market properly to the people that want to hear better. Mrs. Moore became a Hearing Instrument Specialist, just as her father did so she can help people hear better. Kim lives in Granite Bay, CA with her husband, Mark Moore.

Matthew Moore, CEO, Secretary and Director

Matthew Moore was Chief Marketing Officer as ran the day-to-day operations for Moore Family Hearing Company Inc., a chain of hearing aid retail clinics. Matthew specializes in developing print and demographically tailored mail campaigns, as well as monitoring and consulting on Key Business Performance Indicators for all businesses, especially for Audiological Practices. Matthew has the ability and track record of consulting with businesses as well as in his own business streamline efficacies from Top to Bottom and extract better performance from every level of an organization. Matthew is also third generation in the hearing device industry and has literally grown up around the hearing aid industry and entrepreneurship.

Matthew Moore’s expertise is in the senior demographics and customized market analysis for elderly related products including hearing aids across the United States. He lives in Roseville, CA. with his wife and two Children.

Family Relationships

Mark Moore and Kim Moore are married to one another. Matthew Moore is the son of Mark and Kim Moore.

Involvement in Certain Legal Proceedings

No director, executive officer, significant employee or control person of the Company has been involved in any legal proceeding listed in Item 401(f) of Regulation S-K in the past 10 years.

Corporate Governance

Our Board has not established any committees, including an audit committee, a compensation committee or a nominating committee, or any committee performing a similar function. The functions of those committees are being undertaken by our Board. Because we do not have any independent directors, our Board believes that the establishment of committees of our Board would not provide any benefits to our Company and could be considered more form than substance.

We do not have a policy regarding the consideration of any director candidates that may be recommended by our stockholders, including the minimum qualifications for director candidates, nor have our officers and directors established a process for identifying and evaluating director nominees. We have not adopted a policy regarding the handling of any potential recommendation of director candidates by our stockholders, including the procedures to be followed. Our officers and directors have not considered or adopted any of these policies as we have never received a recommendation from any stockholder for any candidate to serve on our Board of Directors.

Given our relative size and lack of directors’ and officers’ insurance coverage, we do not anticipate that any of our stockholders will make such a recommendation in the near future. While there have been no nominations of additional directors proposed, in the event such a proposal is made, all current members of our Board will participate in the consideration of director nominees.

As with most small, early-stage companies until such time as our Company further develops our business, achieves a revenue base and has sufficient working capital to purchase directors’ and officers’ insurance, we do not have any immediate prospects to attract independent directors. When we are able to expand our Board to include one or more independent directors, we intend to establish an audit committee of our Board of Directors. It is our intention that one or more of these independent directors will also qualify as an audit committee financial expert. Our securities are not quoted on an exchange that has requirements that a majority of our Board members be independent, and we are not currently otherwise subject to any law, rule or regulation requiring that all or any portion of our Board of Directors include “independent” directors, nor are we required to establish or maintain an audit committee or other committee of our Board.

Conflicts of Interests

On May 9, 2017, the Company and LLC1 purchased certain real property from an unaffiliated party. The Company and LLC1 have agreed that the Company purchased and owns 49% of the building and LLC1 purchased and owns 51% of the building. On June 14, 2017, the Company entered into a five-year lease with LLC1 for approximately 6,944 square feet and a monthly rent of $12,000. For the year ended December 31, 2020, and 2019, the Company expensed $144,000 and $144,000, respectively, related to this lease.

Code of Ethics

We adopted a Code of Ethics for Senior Financial Management to promote honest and ethical conduct and to deter wrongdoing. This Code applies to our Chief Executive Officer and Chief Financial Officer and other employees performing similar functions. The obligations of the Code of Ethics supplement, but do not replace, any other code of conduct or ethics policy applicable to our employees generally.

Under the Code of Ethics, all members of the senior financial management shall:

•

Act honestly and ethically in the performance of their duties at our company,

•

Avoid actual or apparent conflicts of interest between personal and professional relationships,

•

Provide full, fair, accurate, timely and understandable disclosure in reports and documents that we file with, or submits to, the SEC and in other public communications by our company,

•

Comply with rules and regulations of federal, state and local governments and other private and public regulatory agencies that effect the conduct of our business and our financial reporting,

•

Act in good faith, responsibly, with due care, competence and diligence, without misrepresenting material facts or allowing the member’s independent judgment to be subordinated

•

Respect the confidentiality of information in the course of work, except when authorized or legally obtained to disclosure such information,

•

Share knowledge and maintain skills relevant to carrying out the member’s duties within our company,

•

Proactively promote ethical behavior as a responsible partner among peers and colleagues in the work environment and community,

•

Achieve responsible use of and control over all assets and resources of our company entrusted to the member, and

•

Promptly bring to the attention of the Chief Executive Officer any information concerning (a) significant deficiencies in the design or operating of internal controls which could adversely affect to record, process, summarize and report financial data or (b) any fraud, whether or not material, that involves management or other employees who have a significant role in our financial reporting or internal controls.

Director Independence

None of the members of our Board of Directors qualifies as an independent director in accordance with the published listing requirements of the NASDAQ Global Market. The NASDAQ independence definition includes a series of objective tests, such as that the director is not, and has not been for at least three years, one of our employees and that neither the director, nor any of his family members has engaged in various types of business dealings with us. In addition, our Board has not made a subjective determination as to each director that no relationships exist which, in the opinion of our Board, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director, though such subjective determination is required by the NASDAQ rules. Had our Board of Directors made these determinations, our Board would have reviewed and discussed information provided by the directors and us with regard to each director’s business and personal activities and relationships as they may relate to us and our management.

In performing the functions of the audit committee, our board oversees our accounting and financial reporting process. In this function, our board performs several functions. Our board, among other duties, evaluates and assesses the qualifications of the Company’s independent auditors; determines whether to retain or terminate the existing independent auditors; meets with the independent auditors and financial management of the Company to review the scope of the proposed audit and audit procedures on an annual basis; reviews and approves the retention of independent auditors for any non-audit services; reviews the independence of the independent auditors; reviews with the independent auditors and with the Company’s financial accounting personnel the adequacy and effectiveness of accounting and financial controls and considers recommendations for improvement of such controls; reviews the financial statements to be included in our annual and quarterly reports filed with the Securities and Exchange Commission; and discusses with the Company’s management and the independent auditors the results of the annual audit and the results of our quarterly financial statements.

Our board as a whole considers executive officer compensation, and our entire board participates in the consideration of director compensation. Our board as a whole oversees our compensation policies, plans and programs, reviews and approves corporate performance goals and objectives relevant to the compensation of our executive officers, if any, and reviews the compensation and other terms of employment of our Chief Executive Officer and our other executive officers. Our board also administers our equity incentive and stock option plans, if any.

Each of our directors participates in the consideration of director nominees. In addition to nominees recommended by directors, our board will consider nominees recommended by shareholders if submitted in writing to our secretary. Our board believes that any candidate for director, whether recommended by shareholders or by the board, should be considered on the basis of all factors relevant to our needs and the credentials of the candidate at the time the candidate is proposed. Such factors include relevant business and industry experience and demonstrated character and judgment.

Compliance with Section 16(a) of the Securities Exchange Act of 1934

Section 16(a) of the Securities Exchange Act of 1934, as amended, requires our executive officers and directors, and persons who beneficially own more than 10% of a registered class of our equity securities to file with the SEC initial statements of beneficial ownership, reports of changes in ownership and annual reports concerning their ownership of our common shares and other equity securities, on Forms 3, 4 and 5 respectively. Executive officers, directors and greater than 10% shareholders are required by the SEC regulations to furnish us with copies of all Section 16(a) reports they file. Based solely upon a review of such reports, and on written representations from certain reporting persons, the Company believes that, with respect to the fiscal year ended December 31, 2020 each director, executive officer and 10% stockholder made timely filings of all reports required by Section 16 of the Exchange Act.

ITEM 11. EXECUTIVE COMPENSATION.

The following tables set forth all of the compensation awarded to, earned by or paid to: (i) each individual serving as our principal executive officer; and (ii) each other individual that served as an executive officer at the conclusion of the fiscal year ended December 31, 2020 and who received in excess of $100,000.

Summary Compensation Table

											Non-		Non-
											Equity		qualified
											Incentive		Deferred		All
											Plan		Compen-		Other
							Stock		Option		Compen-		sation		Compen-
			Salary		Bonus		Options		Awards		sation		Earnings		sation (1)		Total
Name and principal position	Year		$		$		$		$		$		$		$		$
Matthew Moore,		2020		225,000		0		0		0		0		0		0		225,000
CEO, Secretary & Director		2019		225,000		0		0		0		0		0		0		225,000
Kim Moore,		2020		150,000		0		0		0		0		0		0		150,000
Treasurer & Director		2019		150,000		0		0		0		0		0		0		150,000
Mark Moore,		2020		0		0		0		0		0		0		0		0
Chairman		2019		0		0		0		0		0		0		0		0

Employment Agreements

On November 15, 2016, the Company executed an employment agreement with Matthew Moore for an annual compensation of $225,000 and with Kimberly Moore for $125,000 annual compensation. On January 1,2019, the Company increased compensation of Kimberly Moore to $150,000 per year.

Outstanding Equity Awards at Fiscal Year-End

No executive officer received any equity awards or holds exercisable or unexercisable options as of December 31, 2020.

Long-Term Incentive Plans

There are no arrangements or plans in which the Company would provide pension, retirement or similar benefits for directors or executive officers.

Compensation Committee

We currently do not have a compensation committee of our Board of Directors. The Board as a whole determines executive compensation.

Director Compensation

We do not pay fees to our directors for attendance at meetings of the board; however, we may adopt a policy of making such payments in the future. We will reimburse out-of-pocket expenses incurred by directors in attending board and committee meetings.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS.

The following table sets forth information known to the Company with respect to the beneficial ownership (as such term is defined in Rule 13d-3 under the Securities Exchange Act of 1934, as amended) of the outstanding common stock of the Company as of April 15, 2019 by: (1) each person known by the Company to beneficially own 5% or more of the Company’s outstanding common stock; (2) each of the named executive officers as defined in Item 402(m)(2); (3) each of the Company’s directors; and (4) all of the Company’s executive officers and directors as a group. The number of shares beneficially owned is determined under rules promulgated by the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Including those shares in the tables does not, however, constitute an admission that the named stockholder is a direct or indirect beneficial owner of those shares. The below table is as of June 30, 2022. As of June 30, 2022, there were 7,323,973,266 shares of common stock issued and outstanding. The Company also has outstanding 900,000 shares of Series B Preferred Stock, which is not convertible but votes on a 1,000 for one basis with the common stock and is considered a “control block” of shares.

Name and Address of Beneficial Owner (1)	Common Stock Beneficially Owned		Percent of Class (2)			Preferred Stock Beneficially Owned		Percent of Class (3)
Mark Moore (4)		19,020,000		0.2	%		300,000		33.33	%
Kimberly Moore (5)		19,020,000		0.2	%		300,000		33.33	%
Matthew Moore (6)		19,020,000		0.2	%		300,000		33.33	%
Officers and Directors as a group, 3 persons (7)		57,060,000		0.6	%		900,000		100.0	%

(1)

Beneficial Ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes voting or investment power with respect to securities.

(2)

Percentages are based on a total of 7,323,973,266 shares of common stock outstanding as of June 30, 2022.

(3)

Percentages are based on a total of 900,000 shares of common stock outstanding as of June 30, 2022.

(4)

Excludes 19,020,000 shares owned by Kimberly Moore, the spouse of Mark Moore.

(5)

Excludes 19,020,000 shares owned by Mark Moore, the spouse of Kimberly Moore.

(6)

Excludes 450,000 shares owned by Margaret May Moore, the spouse of Matthew Moore.

(7)

Includes Matthew Moore shares, Kimberly Moore shares and Mark Moore shares.

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE.

As of December 31, 2020, we had $662,178of the amount payable to related parties as compared to $266,419 as of December 31, 2019. The balance primarily represents advance payable to shareholders and management of the Company on behalf of the Company.

Effective August 1, 2016, the Company agreed to compensation of $225,000 and $125,000 per year for the Company’s CEO and CFO, respectively. On November 15, 2016, the Company entered into employment agreements with its CEO and CFO, which includes their annual base salaries of $225,000 and $125,000, respectively. On January 1, 2019, the Company agreed to increase compensation to $ $150,000 per year for the Company’s CFO.

On June 14, 2017, the Company entered into a five-year lease with LLC1 for approximately 6,944 square feet and a monthly rent of $12,000 (Note 11).

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

The following table shows the fees that were billed for the audit and other services provided by Paris Kreit & Chiu CPA for the years ended December 31, 2020 and 2019.

		2020		2019
Audit Fees	$	—	$	—
Audit-Related Fees		—		—
Tax Fees		—		—
All Other Fees		—		—
Total	$	—	$	—

Audit Fees — This category includes the audit of our annual financial statements, review of financial statements included in our Quarterly Reports on Form 10-Q and services that are normally provided by the independent registered public accounting firm in connection with engagements for those fiscal years. This category also includes advice on audit and accounting matters that arose during, or as a result of, the audit or the review of interim financial statements.

Audit-Related Fees — This category consists of assurance and related services by the independent registered public accounting firm that are reasonably related to the performance of the audit or review of our financial statements and are not reported above under “Audit Fees.” The services for the fees disclosed under this category include consultation regarding our correspondence with the SEC and other accounting consulting.

Tax Fees — This category consists of professional services rendered by our independent registered public accounting firm for tax compliance and tax advice.

All Other Fees — This category consists of fees for other miscellaneous items.

Our board of directors has adopted a procedure for pre-approval of all fees charged by our independent registered public accounting firm. Under the procedure, the board approves the engagement letter with respect to audit, tax and review services. Other fees are subject to pre-approval by the board. All audit and permissible non-audit services provided by the auditors with respect to 2020 and 2019 were pre-approved by the board of directors.

PART IV

ITEM 15. EXHIBITS AND REPORTS.

(a)

1. Financial Statements

The consolidated financial statements and Report of Independent Registered Public Accounting Firm is included on pages F-1 through F-13

Financial Statement Schedules

All schedules for which provisions made in the applicable accounting regulations of the Securities and Exchange Commission (the “Commission”) are either not required under the related instructions, are not applicable (and therefore have been omitted), or the required disclosures are contained in the financial statements included herein.

Exhibits (including those incorporated by reference).

Exhibit Number		Description of Exhibit
3.1*		Articles of Incorporation
3.2*		Bylaws of InnerScope Advertising Agency, Inc.
3.3*		Amended and Restated Articles of Incorporation
3.4*		Amended and Restated Articles of Incorporation dated August 25, 2017
4.3*		Private Placement Offering Memorandum
10.2*		InnerScope, Inc. Marketing Agreement between the Company and Moore Family Hearing Company, Inc.
10.3*		Acquisition Agreement and Plan of Share Exchange dated June 20, 2012, between the Company and InnerScope Advertising Agency, LLC
10.4*		Acquisition Agreement and Plan of Share Exchange dated November 1, 2013, between the Company and Intela-Hear, LLC
10.5*		Promissory Note dated April 1, 2013, between the Company and Matthew Moore
10.6*		Promissory Note dated June 25, 2013, between the Company and Matthew Moore
10.7*		June 2012 Business Consulting Agreement
10.8+*		GN ReSound Sales Agreement
10.9+*		Store Expansion Consulting Agreement
10.10+*		Consulting Agreement
10.11#*		Employment Agreement with Matthew Moore, CEO
10.12#*		Employment Agreement with Kimberly Moore, CFO
10.13*		Financial Consulting Agreement between the Company and Venture Equity, LLC
10.14*		Consulting and Representation Agreement between the Company and CorporateAds.com
10.15*		Business Loan Agreement, dated May 5, 2017, between InnerScope Advertising Agency, Inc. and Moore Holdings, LLC and First Community Bank.
10.16*		Commercial Security Agreement, dated May 5, 2017, between InnerScope Advertising Agency, Inc. and Moore Holdings, LLC and First Community Bank.
10.17*		U.S. Small Business Administration Note.
10.18*		Deed of Trust, dated May 5, 2017, among InnerScope Advertising Agency, Inc. and Moore Holdings, LLC. and First Community Bank and Placer Title Company.
10.19*		Securities Purchase Agreement dated October 5, 2017 by and between InnerScope Hearing Technologies, Inc. and Power Up Lending Group, LTD.
10.20*		Convertible Promissory Note dated October 5, 2017, by and between InnerScope Hearing Technologies, Inc. and Power Up Lending Group, LTD.
10.21*		Securities Purchase Agreement dated November 10, 2017, by and between InnerScope Hearing Technologies, Inc. and Carebourn Capital, L.P.
10.22*		Convertible Promissory Note dated November 10, 2017, by and between InnerScope Hearing Technologies, Inc. and Carebourn Capital, L.P.
10.23*		Securities Purchase Agreement dated February 8, 2018 by and between InnerScope Hearing Technologies, Inc. and Power Up Lending Group, LTD.
10.24*		Convertible Promissory Note dated February 8, 2018, by and between InnerScope Hearing Technologies, Inc. and Power Up Lending Group, LTD.
10.25*		Securities Purchase Agreement dated April 8, 2019, by and between InnerScope Hearing Technologies, Inc. and Carebourn Capital, L.P.
10.26*		Convertible Promissory Note dated April 8, 2018, by and between InnerScope Hearing Technologies, Inc. and Carebourn Capital, L.P.
10.27*		Securities Purchase Agreement dated May 11, 2018, by and between InnerScope Hearing Technologies, Inc. and One44 Capital LLC
10.28*		Convertible Promissory Note dated May 11, 2018, by and between InnerScope Hearing Technologies, Inc. and One44 Capital LLC
10.29*		Convertible Back- End Promissory Note dated May 11, 2018, by and between InnerScope Hearing Technologies, Inc. and One44 Capital LLC
10.30*		Mutual Settlement Agreement and Release with Helix Hearing Care (California), Inc.
10.31*		Manufacturing Design and Marketing Agreement.
10.32*		Securities Purchase Agreement between InnerScope Hearing Technologies, Inc. and Eagle Equities, LLC, dated November 2, 2018.
10.33*		Form of 8% Convertible Redeemable Notes issued by Company to Eagle Equities, LLC, dated November 2, 2018.

10.34*		$255,500 Principal Amount 8% Collateralized Secured Promissory Note issued by Eagle Equities, LLC.
10.35*		First Amendment to Manufacturing Design and Marketing Agreement (the “Zounds Agreement”) between InnerScope Hearing Technologies, Inc. and Zounds Hearing, Inc., a Delaware corporation (“Zounds”), dated November 2, 2018
10.36*		Joint Development Agreement between InnerScope Hearing Technologies, Inc. and Erchonia Corporation.
10.37*		Exclusive Distributor Agreement between InnerScope Hearing Technologies, Inc. and Erchonia Corporation.
31.1**		Rule 13a-14(a)/15d-14(a) Certification of Principal Executive Officer
31.2**		Rule 13a-14(a)/15d-14(a) Certification of Principal Financial Officer
32.1**		Section 1350 Certification of Chief Executive Officer and Chief Financial Officer
101.INS**		XBRL Instance
101.SCH**		XBRL Taxonomy Extension Schema
101.CAL**		XBRL Taxonomy Extension Calculation Linkbase
101.DEF**		XBRL Taxonomy Extension Definition Linkbase
101.LAB**		XBRL Taxonomy Extension Labels Linkbase
101.PRE**		XBRL Taxonomy Extension Presentation Linkbase

* Previously filed.

+ Confidential Treatment has been requested for certain portions thereof pursuant to Confidential Treatment Request under Rule 406 promulgated under the Securities Act. Such provisions and attachments have been filed with the Securities and Exchange Commission.

** Filed Herewith

# Denotes management contract or compensatory plan or arrangement.

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

InnerScope Hearing Technologies, Inc.

By: /s/ Matthew Moore

Matthew Moore

Chief Executive Officer

Date: September 13, 2022

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Mark Moore	Chairman	September 13, 2022
Mark Moore /s/ Matthew Moore	Chief Executive Officer, CEO and	September 13, 2022
Matthew Moore /s/ Kimberly Moore	Director (Principal Executive Officer) Chief Financial Officer and Director	September 13, 2022
Kimberly Moore	(Chief Accounting Officer)

INNERSCOPE HEARING TECHNOLOGIES, INC.

FOR THE YEARS ENDED DECEMBER 31, 2020 AND 2019

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

Report of Independent Registered Public Accounting Firm	F-2
Consolidated Balance Sheets as of December 31, 2020 and 2019	F-3
Consolidated Statements of Operations for the years ended December 31, 2020 and 2019	F-4
Consolidated Statement of Changes in Stockholders’ Deficit for the years ended December 31, 2020 and 2019	F-5
Consolidated Statements of Cash Flows for the years ended December 31, 2020 and 2019	F-6
Notes to Consolidated Financial Statements	F-7 – F-27

F-1

Paris, Kreit & Chiu CPA LLP

200 Park Ave, Suite 1700

New York, NY 10166

(949) 326-CPAS (2727)

Report of Independent Registered Public Accounting Firm

Board of Directors and Stockholders

InnerScope Hearing Technologies, Inc.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of InnerScope Hearing Technologies, Inc. as of December 31, 2020 and 2019, and the related consolidated statements of operations, stockholders’ deficit, and cash flows for the years then ended, and the related notes to the consolidated financial statements. In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of InnerScope Hearing Technologies, Inc. as of December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the years then ended in conformity with accounting principles generally accepted in the United States of America.

Going Concern

The accompanying consolidated financial statements have been prepared assuming that the entity will continue as a going concern. As discussed in Note 3 to the consolidated financial statements, the entity has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management's plans in regard to these matters are also described in Note 3. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the entity’s management. Our responsibility is to express an opinion on these financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to InnerScope Hearing Technologies, Inc. in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. InnerScope Hearing Technologies, Inc. is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

Paris Kreit & Chiu CPA LLP

Paris, Kreit & Chiu CPA LLP

We have served as InnerScope Hearing Technologies, Inc.'s auditor since 2021.

New York, NY

September 12, 2022

F-2

INNERSCOPE HEARING TECHNOLOGIES, INC.

CONSOLIDATED BALANCE SHEETS


	As of December 31,
	2020			2019
ASSETS
Current Assets:
Cash	$	i 3,349		$	i 4,459
Accounts receivable, allowance for doubtful accounts		i 12,429			i 51,160
Accounts receivable from related party		—			—
Employee advances		i 3,000			i 3,750
Prepaid assets		—			i 73,249
Inventory		i 4,671			i 18,781
Total current assets		i 23,449			i 151,399

Security deposits		i 4,863			i 12,752
Domain name		i 3,000			i 3,000
Intangible assets, net of accumulated amortization		—			i 879,336
Property and equipment, net of accumulated depreciation		i 60,203			i 72,241
Operating leases right-of-use assets, net		i 364,062			i 846,132
Investment in undivided interest in real estate		i 1,227,733			i 1,210,526
Total assets	$	i 1,683,310		$	i 3,175,386

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities:
Bank overdraft	$	i 271		$	i 2,631
Accounts payable and accrued expenses		i 1,841,300			i 1,316,185
Accounts payable to related party		i 662,178			i 266,419
Notes payable - stockholder		i 95,800			i 95,800
Current portion of convertible notes payable, net of discounts		i 3,255,598			i 2,390,481
Note payable, other and related party		i 118,786			i 106,942
Customer deposits		i 10,925			i 21,505
Current portion of note payable- undivided interest in real estate		i 22,150			i 20,708
Derivative liabilities		i 4,046,401			i 3,515,055
Operating lease liabilities, current portion		i 365,587			i 299,794
Total current liabilities		i 10,418,996			i 8,035,520

Long term portion of note payable- undivided interest in real estate		i 938,003			i 952,884
PPP loan		i 262,445			—
Operating lease liabilities, Less current portion		i 416,788			i 731,496
Total liabilities	$	i 12,036,232			i 9,719,900

Commitments and contingencies
Stockholders' Deficit:
Preferred stock, $ i i 0.0001 / par value; i i 25,000,000 / shares authorized;
Series A preferred stock, par value $ i i 0.0001 / , - i i 0 / - (2020) and - i i 0 / - (2019)		—			—
Series B preferred stock, par value $ i i 0.0001 / , i 900,000 (2020) and i 900,000 (2019) shares authorized, and i i 900,000 / (2020) and i i 900,000 / (2019) shares issued and outstanding		i 90			i 90
Common stock, $ i i 0.0001 / par value; i 14,975,000,000 (2020) and i 14,975,000,000 (2019) shares authorized and i i 3,628,422,042 / (2020) and i i 342,118,136 / (2019) shares issued and outstanding		i 362,845			i 34,212
Common stock to be issued, $ i i 0.0001 / par value, i 2,412,671 (2020) and i 2,412,671 (2019) shares		i 241			i 241
Additional paid-in capital		i 8,534,062			i 7,717,411
Accumulated deficit		( i 19,250,160	)		( i 14,296,468	)
Total stockholders' deficit		( i 10,352,922	)		( i 6,544,514	)
Total Liabilities and Stockholders' Equity	$	i 1,683,310		$	i 3,175,386

See notes to consolidated financial statements.

F-3

INNERSCOPE HEARING TECHNOLOGIES, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS


	Year Ended December 31st,
	2020			2019
Revenues:
Revenues, other	$	i 166,111		$	i 802,109
Revenues, related party		—			i 45,000
Total revenues		i 166,111			i 847,109

Cost of sales
Cost of sales, other		i 68,768			i 496,736
Total cost of sales		i 68,768			i 496,736

Gross profit		i 97,343			i 350,374

Operating Expenses:
Compensation and benefits		i 661,840			i 1,575,395
Advertising and promotion		i 19,762			i 485,407
Professional fees		i 114,476			i 763,157
Rent, including related party		i 322,879			i 424,613
Investor relations		i 14,796			i 193,696
Depreciation and Amortization expense		i 123,646			i 150,024
Other general and administrative		i 69,188			i 502,908
Total operating expenses		i 1,326,587			i 4,095,200

Loss from operations		( i 1,229,244	)		( i 3,744,826	)

Other Income (Expense):
Other income
Derivative income (loss)		( i 1,066,904	)		( i 647,633	)
Gain on equity investment		i 30,646			i 15,083
Amortization of debt discount		( i 1,222,965	)		( i 2,954,879	)
Loss on debt extinguishment		—			( i 52,702	)
Loss on lease termination		( i 201,283	)		( i 146,337	)
Other income (expenses)		i 181			( i 6,742	)
Loss on intangibles		( i 775,000	)		—
Interest expense and finance charges		( i 489,123	)		( i 386,303	)
Total other income (expense), net		( i 3,724,448	)		( i 4,179,513	)

Loss before income tax		( i 4,953,692	)		( i 7,924,339	)

Income tax provision		—			—

Net Loss	$	( i 4,953,692	)	$	( i 7,924,339	)

Basic and diluted income (loss) per share		( i 0.00	)		( i 0.02	)

Weighted average number of common shares outstanding
Basic and diluted		i 2,769,472,382			i 486,708,071

See notes to consolidated financial statements.

F-4

INNERSCOPE HEARING TECHNOLOGIES, INC.

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT

YEARS ENDED DECEMBER 31, 2020 and 2019

Series B Preferred stock

Common stock

Deferred stock

Common stock to be issued

Additional Paid-in

Retained

Total Stockholders'

Amount

Compensation

Amount

Capital

deficit

Deficit

Balances December 31, 2018

i 900,000

i 90

i 120,425,344

i 12,042

( i 235,694

)

i 6,376,848

i 637

i 4,836,556

( i 6,372,129

)

( i 1,758,498

)

Amortization of deferred stock compensation

—

i 235,694

—

i 235,694

Issuance of stock for services

—

i 12,576,313

i 1,258

—

( i 3,961,177

)

( i 396

)

i 439,804

—

i 440,666

Related party contribution

—

i 12,048

—

i 12,048

Debt conversion and retirement of derivative liabilities

—

i 209,116,478

i 20,912

—

i 2,429,003

—

i 2,449,915

Net loss for the period ended December 31, 2019

—

( i 7,924,339

)

( i 7,924,339

)

Balances December 31, 2019

i 900,000

i 90

i 342,118,135

i 34,212

—

i 2,415,671

i 241

i 7,717,411

( i 14,296,468

)

( i 6,544,514

)

Debt conversion and retirement of derivative liabilities

—

i 3,286,303,906

i 328,633

—

i 816,651

—

i 1,145,284

Net loss for the period ended December 31, 2020

—

( i 4,953,692

)

( i 4,953,692

)

Balances December 31, 2020

i 900,000

i 90

i 3,628,422,041

i 362,845

—

i 2,415,671

i 241

i 8,534,062

( i 19,250,160

)

( i 10,352,922

)

See notes to consolidated financial statements.

F-5

INNERSCOPE HEARING TECHNOLOGIES, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS


	Year Ended December 31,
	2020			2019
Cash flows from operating activities:
Net loss	$	i 4,953,692		$	i 7,924,339
Adjustments to reconcile net loss to net cash used in operations:
Depreciation and amortization		i 123,646			i 150,024
Gain/Loss on settlement of debt		—			i 44,852
Loss on lease termination		( i 11,020	)		i 5,426
Loss on ROU asset		i 204,416			i 167,938
Discount amortization		i 1,172,111			i 2,850,033
Derivative loss (gain)		i 1,066,904			i 647,633
Stock-based compensation		—			i 440,667
Gain/Loss on equity investment		(30,646	)		15,083
Loss on intangibles		i 775,000			—
Changes in operating assets and liabilities:
Accounts receivable		i 38,732			( i 45,048	)
Inventory		i 14,110			i 72,729
Pre-paids and other current asset		i 73,999			i 369,930
Related party receivable		—			i 203,325
Security deposit		i 7,889			( i 1,696	)
Accounts payable		i 570,077			( i 130,405	)
Customer deposits		( i 10,580	)		( i 35,193	)
Related party advances		i 395,759			i 231,310
Changes in lease liability		i 39,761			i 11,790
Net cash used in operating activities		( i 523,534	)		( i 2,925,941	)

Cash flows from investing activities:
Changes in intangibles		—			—
Purchase/Sale of office and computer equipment		( i 7,272	)		( i 49,614	)
Equity investment		—			( i 9,561	)
Net cash used in investing activities		( i 7,272	)		( i 59,175	)

Cash flows from financing activities:
Proceeds from related party contribution		—			i 12,048
Payments/Proceeds from convertible notes payable		i 269,611			i 2,854,250
Proceeds/payments from notes payable		—			i 32,820
Bank overdraft		( i 2,360	)		i 2,631
Proceeds from pay check protection program loan		i 262,445			—
Net cash provided by financing activities		i 529,696			i 2,901,749

Net decrease in cash and cash equivalents		( i 1,110	)		( i 83,367	)

Cash and cash equivalents, beginning of year	$	i 4,459		$	i 87,826

Cash and cash equivalents, end of year	$	i 3,349		$	i 4,459

Supplemental disclosure of cash flow information:
Cash paid for interest		—			—
Cash paid for income taxes		—			—

Schedule of non-cash Investing or Financing Activity:
Reclassification of derivative liabilities upon principal repayments of convertible notes		i 684,355			i 1,322,092
Conversion of notes payable and accrued interest in common stock		i 460,929			i 1,127,823
Operating lease right-of-use assets and liabilities		—			i 1,038,580

See notes to consolidated financial statements.

F-6

NOTE 1 – ORGANIZATION

Business

InnerScope Hearing Technologies, Inc. (“Company”, “InnerScope”) is a Nevada Corporation incorporated on June 15, 2012, with its principal place of business in Roseville, California. The Company was originally named InnerScope Advertising Agency, Inc. and was formed to provide advertising and marketing services to retail establishments in the hearing device industry. On August 25, 2017, the Company changed its name to InnerScope Hearing Technologies, Inc. to better reflect the Company’s current direction as a hearing health technology company that manufactures, develops, distributes, and sells numerous innovative hearing health-related products, hearing treatments, and hearing solutions direct to consumer (DTC) with a scalable business model.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING PRINCIPLES

Basis of Presentation and Principles of Consolidation

Emerging Growth Companies

Use of Estimates

Cash and Cash Equivalents

The Company considers all highly liquid investments with an original term of three months or less to be cash equivalents. These investments are carried at cost, which approximates fair value. The Company held no cash equivalents as of December 31, 2020 and 2019. Cash balances may, at certain times, exceed federally insured limits. If the amount of a deposit at any time exceeds the federally insured amount at a bank, the uninsured portion of the deposit could be lost, in whole or in part, if the bank were to fail. No losses have been recognized as a result of these excess amounts.

Accounts receivable

The Company records accounts receivable at the time products and services are delivered. An allowance for losses is established through a provision for losses charged to expenses. Receivables are charged against the allowance for losses when management believes collectability is unlikely. The allowance (if any) is an amount that management believes will be adequate to absorb estimated losses on existing receivables, based on evaluation of the collectability of the accounts and prior loss experience. As of December 31, 2020 and 2019, management’s evaluation required the establishment of an allowance for uncollectible receivables of $27,991 and $27,615, respectively.

Sales Concentration and Credit Risk

Following is a summary of customers who accounted for more than ten percent (10%) of the Company’s revenues for the years ended December 31, 2020 and 2019, and accounts receivable balances as of December 31, 2020 and 2019:

December 31,

Accounts Receivable as of

2020

2019

December 31, 2020

December 31, 2019

Customer A

i 28%

i 5%

i 0%

i 41%

Inventory

Inventory is valued at the lower of cost or net realizable value. Cost is determined using the first in first out (FIFO) method. Provision for potentially obsolete or slow-moving inventory is made based on management analysis or inventory levels and future sales forecasts. As of December 31, 2020, and 2019, management’s analysis did not require any provisions to be recognized.

F-7

Intangible Assets

Costs for intangible assets are accounted for through the capitalization of those costs incurred in connection with developing or obtaining such assets. Capitalized costs are included in intangible assets in the consolidated balance sheets. On October 3, 2018, the Company entered into a Manufacturing Design and Marketing Agreement (the “Agreement”) with Zounds Hearing, Inc., a Delaware corporation (“Zounds”), whereby, Zounds as the Subcontractor will provide design, technology, manufacturing and supply chain services to the Company (see Note 13) for a period of ten years. The Company will pay Zounds One Million ($1,000,000) for the right to use proprietary technology (the “Technology Access Fee”). As of December 31, 2018, the Company has capitalized the $1,000,000 Technology Access Fee as an intangible asset on the consolidated balance sheets. The Technology Access Fee will be amortized over the term of the Agreement. The Company also acquired intangible assets from an asset purchase agreement (see Note 4). During the year ended December 31, 2020, the Company determined that they do not expect to realize any benefit in the foreseeable future, therefore, have recorded an impairment of $775,000.

Property and Equipment

Property and equipment are stated at cost, and depreciation is provided by use of a straight-line method over the estimated useful lives of the assets. The Company reviews property and equipment for potential impairment whenever events or changes in circumstances indicate that the carrying amounts of assets may not be recoverable. The estimated useful lives of property and equipment are as follows:

Computer equipment	3 years
Machinery and equipment	5 years
Furniture and fixtures	5 years
Leasehold improvements	3-5 years

The Company's property and equipment consisted of the following at December 31, 2020, and 2019:

	December 31, 2020			December 31, 2019
Computer and equipment	$	i 4,272		$	i 4,272
Leasehold improvements		i 12,222			i 12,222
Machinery and equipment		i 45,411			i 38,139
Furniture and equipment		i 39,152			i 39,152
		101,057			93,785
Accumulated depreciation		( i 40,854	)		( i 21,544	)
Property and equipment, net	$	i 60,203		$	i 72,241

Depreciation expense of $19,310 and $25,453 was recorded for the years ended December 31, 2020 and 2019, respectively.

Investment in Undivided Interest in Real Estate

The Company accounts for its’ investment in undivided interest in real estate using the equity method, as the Company is severally liable only for the indebtedness incurred with its interest in the property. The Company includes its allocated portion of net income or loss in Other income (expense) in its Statement of Operations, with the offset to the equity investment account on the balance sheet. For the years ended December 31, 2020 and 2019, the Company recognized a gains of $30,646 and $15,083, respectively. As of December 31, 2020, and 2019, the carrying value of the Company’s investment in undivided interest in real estate was $1,227,733 and $1,210,526, respectively (see Note 9).

Fair Value of Financial Instruments

The Company measures assets and liabilities at fair value based on an expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that mark et participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

The following are the hierarchical levels of inputs to measure fair value:

•

Level 1 - Observable inputs that reflect quoted market prices in active markets for identical assets or liabilities.

•

F-8

The carrying amounts of the Company's financial assets and liabilities, such as cash, prepaid expenses, accounts receivable, accounts payable and accrued expenses, certain notes payable and notes payable - related party, approximate their fair values because of the short maturity of these instruments. The following table represents the Company’s financial instruments that are measured at fair value on a recurring basis as of December 31, 2020, and 2019, for each fair value hierarchy level:

December 31, 2019

Level 1

Level 2

Level 3

Total

Derivative liabilities

—

i 3,515,055

—

i 3,515,055

December 31, 2020

Level 1

Level 2

Level 3

Total

Derivative liabilities

—

i 4,046,401

—

i 4,046,401

Embedded Conversion Features

The Company evaluates embedded conversion features within convertible debt under ASC 815 "Derivatives and Hedging" to determine whether the embedded conversion feature(s) should be bifurcated from the host instrument and accounted for as a derivative at fair value with changes in fair value recorded in earnings. If the conversion feature does not require derivative treatment under ASC 815, the instrument is evaluated under ASC 470-20 "Debt with Conversion and Other Options" for consideration of any beneficial conversion feature.

Derivative Financial Instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market, or foreign currency risks. The Company evaluates all of it financial instruments, including stock purchase warrants, to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported as charges or credits to income.

For option-based simple derivative financial instruments, the Company uses the Monte Carlo simulations to value the derivative instruments at inception and subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is re- assessed at the end of each reporting period.

Debt Issue Costs and Debt Discount

The Company may record debt issue costs and/or debt discounts in connection with raising funds through the issuance of debt. These costs may be paid in the form of cash, or equity (such as warrants). These costs are amortized to interest expense through the maturity of the debt. If a conversion of the underlying debt occurs prior to maturity a proportionate share of the unamortized amounts is immediately expensed. Any unamortized debt issue costs and debt discount are presented net of the related debt on the consolidated balance sheets.

Original Issue Discount

For certain convertible debt issued, the Company may provide the debt holder with an original issue discount. The original issue discount would be recorded to debt discount, reducing the face amount of the note and is amortized to interest expense through the maturity of the debt. If a conversion of the underlying debt occurs prior to maturity a proportionate share of the unamortized amounts is immediately expensed. Any unamortized original issue discounts are presented net of the related debt on the consolidated balance sheets.

Revenue Recognition

Effective January 1, 2018, the Company adopted ASC Topic 606, “Revenue from Contracts with Customers” (“ASC 606”) and all the related amendments. The Company elected to adopt this guidance using the modified retrospective method. The adoption of this guidance did not have a material effect on the Company’s financial position, results of operations or cash flows.

The core principle of ASC 606 requires that an entity recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. ASC 606 defines a five-step process to achieve this core principle and, in doing so, it is possible more judgment and estimates may be required within the revenue recognition process than required under U.S. GAAP including identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation.

F-9

The Company’s contracts with customers are generally on a purchase order basis and represent obligations that are satisfied at a point in time, as defined in the new guidance, generally upon delivery or has services are provided. Accordingly, revenue for each sale is recognized when the Company has completed its performance obligations, Any costs incurred before this point in time, are recorded as assets to be expensed during the period the related revenue is recognized. The Company accepts prepayments on hearing aids and records the amount received as customer deposits on its’ balance sheet. When the Company delivers the hearing aid to the customer, revenue is recognized as well as the corresponding cost of sales.

As of December 31, 2020 and 2019, the Company had received $21,505 and $10,925 of customer deposits, where revenue will be recognized when the hearing aids are delivered to the customer.

Income Taxes

Advertising and Marketing Expenses

The Company expenses advertising and marketing costs as incurred. For the years ended December 31, 2020 and 2019, advertising and marketing expenses were $19,762 and $485,407, respectively.

Earnings (Loss) Per Share

The Company reports earnings (loss) per share in accordance with ASC 260, "Earnings per Share." Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average number of shares of common stock outstanding during each period. Diluted earnings per share is computed by dividing net loss by the weighted-average number of shares of common stock, common stock equivalents and other potentially dilutive securities outstanding during the period. As of December 31, 2020, and 2019, the Company’s outstanding convertible debt is convertible into approximately 4,650,854,286 and 155,226,039 shares of common stock, respectively. This amount is not included in the computation of dilutive loss per share because their impact is antidilutive.

Recent Accounting Pronouncements

In August 2018, the FASB issued ASU 2018-13, “Changes to Disclosure Requirements for Fair Value Measurements”, which will improve the effectiveness of disclosure requirements for recurring and nonrecurring fair value measurements. The standard removes, modifies, and adds certain disclosure requirements, and is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019 (for “emerging growth company” beginning after December 15, 2020). The Company will be evaluating the impact this standard will have on the Company’s consolidated financial statements.

The FASB recently issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470- 20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity, to reduce complexity in applying GAAP to certain financial instruments with characteristics of liabilities and equity. The guidance in ASU 2020-06 simplifies the accounting for convertible debt instruments and convertible preferred stock by removing the existing guidance in ASC 470-20, Debt: Debt with Conversion and Other Options, which requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host convertible debt or preferred stock. The guidance in ASC 470-20 applies to convertible instruments for which the embedded conversion features are not required to be bifurcated from the host contract and accounted for as derivatives. In addition, the amendments revise the scope exception from derivative accounting in ASC 815-40 for freestanding financial instruments and embedded features that are both indexed to the issuer’s own stock and classified in stockholders’ equity, by removing certain criteria required for equity classification. These amendments are expected to result in more freestanding financial instruments qualifying for equity classification (and, therefore, not accounted for as derivatives), as well as fewer embedded features requiring separate accounting from the host contract. The amendments in ASU 2020-06 further revise the guidance in ASC 260, Earnings Per Share, to require entities to calculate diluted earnings per share (EPS) for convertible instruments by using the if-converted method. In addition, entities must presume share settlement for purposes of calculating diluted EPS when an instrument may be settled in cash or shares. The amendments in ASU 2020-06 are effective for public entities for fiscal years beginning after December 15, 2021, with early adoption permitted (for “emerging growth company” beginning after December 15, 2023). The Company will be evaluating the impact this standard will have on the Company’s consolidated financial statements.

F-10

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842). In July 2018, the FASB issued ASU No. 2018-10, Codification Improvements to Topic 842, Leases (ASU 2018-10), which provides narrow amendments to clarify how to apply certain aspects of the new lease standard, and ASU No. 2018-11, Leases (Topic 842)—Targeted Improvements (ASU 2018-11), which addressed implementation issues related to the new lease standard. These and certain other lease-related ASUs have generally been codified in ASC 842. ASC 842 supersedes the lease accounting requirements in ASC Topic 840, Leases (ASC 840). ASC 842 establishes a right-of-use model that requires a lessee to record a right-of-use asset and a lease liability on the balance sheet for all leases. Under ASC 842, leases are classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. ASU 2016-02 was effective for annual reporting periods beginning after December 15, 2018 and interim periods within that reporting period (for “emerging growth company” from January 1, 2020). The Company adopted ASC 842 on January 1, 2019 using the effective date transition method.

The Company elected the practical expedient to not record short-term leases on its consolidated balance sheet.

NOTE 3 – GOING CONCERN AND MANAGEMENT’S PLANS

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which assumes the realization of assets and satisfaction of liabilities and commitments in the normal course of business. The Company experienced a net loss of $4,953,692 for the year ended December 31, 2020. At December 31, 2020, the Company had a working capital deficit of $10,395,547, and an accumulated deficit of $19,250,160. These factors raise substantial doubt about the Company’s ability to continue as a going concern and to operate in the normal course of business. The Company’s ability to continue as a going concern is dependent upon obtaining the necessary financing to meet our obligations and repay our liabilities arising from normal business operations when they come due and / or generating profitable operations in the future. Management believes that actions presently being taken to further implement our business plan will generate additional revenues and eventually positive cash flow and provide opportunity for the Company to continue as a going concern. While we believe in the viability of our strategy to generate additional revenues and our ability to raise additional funds, there can be no assurances to that effect. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.

NOTE 4 – INTANGIBLE ASSETS, NET (OTHER THAN GOODWILL)

The Company’s intangible assets consist of a customer list and non-compete acquired in 2018 and a Technology Access Fee required to be paid by the Company in connection with a manufacturing design and marketing agreement executed with a supplier (see Note 11). During the year ended December 31, 2020, the Company determined that it was unable to substantiate the actual fair value of the technology that was acquired so has chosen to impair the full amount. These intangible assets are amortized over their estimated useful lives as indicated below. The estimated useful lives of property and equipment are as follows:

Customer List	2 years
Non-compete	2 years
Technology Access Fee	10 years

The Company's intangibles consisted of the following at December 31, 2020, and 2019:

	December 31, 2020			December 31, 2019
Customer List	$	i 300		$	i 300
Non-Compete		i 12,708			i 12,708
Technology Access Fee		—			i 1,000,000
Intellectual Property		i 3,000			i 3,000
Intangibles		i 16,008			i 1,016,008
Accumulated amortization		( i 13,008	)		( i 133,672	)
Intangibles, net	$	i 3,000		$	i 882,336

The Company recognized $104,336 and $124,571 of amortization expense during the years ended December 31, 2020 and 2019.

F-11

NOTE 5 – NOTE PAYABLE, STOCKHOLDER

A summary of the activity for the years ended December 31, 2020, and 2019, of amounts the Company’s CEO (stockholder) loaned the Company and amounts repaid is as follows:

	December 31, 2020		December 31, 2019
Beginning Balance	$	i 95,800	$	i 95,800
Amounts loaned/repaid		—		—
Ending Balance	$	i 95,800	$	i 95,800

The ending balance amount is due on demand, carries interest at 8% per annum and is included Accounts payable and accrued expenses on the consolidated balance sheets included herein.

NOTE 6 – NOTE PAYABLE

In October of 2018, the Company entered into a Business Loan Agreement (the “October BLA”) for $47,215 with a third- party, whereby the Company received

$35,500 on October 10, 2018. The October BLA requires the Company to make the first six monthly payments of principal and interest of $4,467 per month, and then $3,402 for months seven through t12. The note carries a 33% interest rate and matures on October 28, 2019. The Company paid the note in full during the year ending December 31, 2019.

In July of 2019, the Company entered into a Loan Agreement for $60,000 with a third- party. The loan requires the Company to make weekly payments of $1,538. As of December 31, 2020, and 2019, the note balance is $50,581 and $50,581.

In November of 2019, the Company entered into a Loan Agreement for $87,000 with a third- party, whereby the Company received $58,000. The loan requires the Company to make weekly payments of principal and interest of $790. As of December 31, 2020, and 2019, the note balance is $56,945 and $37,938, net of unamortized discounts of $0 and $21,380 respectively.

In December of 2019, the Company entered into a Loan Agreement for $21,750 with a third- party. The loan requires the Company to make weekly payments of principal and interest of $255. As of December 31, 2020, and 2019, the note balance is $11,258 and $18,423.

NOTE 7 – RELATED PARTY TRANSACTIONS

As of December 31, 2020, we had $662,178 of the amount payable to related parties as compared to $266,419 as of December 31, 2019. The balance primarily represents advance payable to shareholders and management of the Company on behalf of the Company.

	Year ended		Year ended
Description	December 31, 2020		December 31, 2019
CEO	$	i 225,000	$	i 225,000
CFO		i 150,000		i 150,000
Total	$	i 375,000	$	i 375,000

On June 14, 2017, the Company entered into a five-year lease with LLC1 for approximately 6,944 square feet and a monthly rent of $12,000 (Note 11).

F-12

NOTE 8– INVESTMENT IN UNDIVIDED INTEREST IN REAL ESTATE

The Company accounts for its investment in undivided interest in real estate as an equity method investment and recognizes its proportionate share of profits and losses. For the years ended December 31, 2020, and 2019, a net gain of $30,646 and $15,736, respectively, is included on the Statements of Operations. As of December 31, 2020, the carrying value of the Company’s investment in undivided interest in real estate was $1,227,733.

The consolidated balance sheets as of December 31, 2020, and 2019 and the statement of operations for the years ended December 31, 2020, and 2019, for the real property is as follows:

Current assets:	2020		2019
Cash	$	i 25,144	$	—
Accounts Receivable		i 125,698		i 106,163
Due from InnerScope		i 138,360		i 79,934
Prepaid expenses and other current assets		i 8,848		—
Total current assets		i 298,050		i 186,097
Land and Building, net		i 2,267,156		i 2,310,722
Other Assets, net		i 43,729		i 45,943
Total assets	$	i 2,608,935	$	i 2,542,762

Accounts Payable	$	i 119,446	$	i 72,475
Current portion of mortgage payable		i 22,150		i 20,708
Other current liabilities		i 37,399		i 16,104
Total current liabilities		i 178,995		i 109,287
Mortgage payable, long-term		i 1,937,345		i 1,966,215
Security deposits		i 3,283		i 13,064
Total liabilities		i 2,119,623		i 2,088,566
Total equity		i 489,312		i 454,196
Total liabilities and equity	$	i 2,608,935	$	i 2,542,762


		2020		2019
Rental income	$	i 243,986	$	i 297,383
Expenses:
Property taxes		i 30,185		i 29,605
Depreciation and amortization		i 45,780		i 50,940
Insurance		i 9,559		i 18,783
Repairs and maintenance		—		i 6,202
Utilities and other		i 45,654		i 68,156
Interest expenses		i 77,692		i 113,858
Total expenses		i 208,870		i 287,544
Net income (loss)	$	i 35,116	$	i 9,839

NOTE 9– CONVERTIBLE NOTES PAYABLE - UNDIVIDED INTEREST IN REAL ESTATE

On May 9, 2017, the Company and LLC1 purchased certain real property from an unaffiliated party. The Company and LLC1 have agreed that the Company purchased and owns 49% of the building and LLC1 purchased and owns 51% of the building. The contracted purchase price for the building was $2,420,000 and the total amount paid at closing was $2,501,783 including, fees, insurance, interest and real estate taxes. The Company is a co-borrower on a $2,057,000 Small Business Administration Note (the “SBA Note”). The SBA Note carries a 25-year term, with an initial interest rate of 6% per annum, adjustable to the Prime interest rate plus 2% (6.75% as of December 31, 20120, and is secured by a first position Deed of Trust and business assets located at the property. The Company initially recorded a liability of $1,007,930 for its portion of the SBA Note, with the offset being to Investment in undivided interest in real estate on the consolidated balance sheets presented herein. As of December 31, 2020, the Company’s current and long-term portion of the SBA Note is $0 and $960,153, respectively. Future principal payments for the Company’s portion are:

F-13

Twelve months ending December 31,	Amount
2021	$	i 22,150
2022		i 23,516
2023		i 24,966
2024		i 26,500
2025		i 28,118
Thereafter		i 834,903
Total	$	i 960,153

On March 2, 2018, the Company completed the closing of a private placement financing transaction (the “Transaction”) when a third-party investor purchased a convertible note (the “Convertible Note”). The Convertible Note carries a 10% annual interest rate and is in the principal amount of $50,000. Principal and interest was due and payable March 2, 2019, and the Note is convertible into shares of the Company’s common stock at any time after one hundred eighty (180) days, at a conversion price (the “Conversion Price”) equal to seventy-five percent (75%) of the average closing price of the Company’s common stock for the ten (10) days immediately preceding the conversion, representing a twenty-five percent (25%) discount. The embedded conversion feature included in the note resulted in an initial debt discount of $13,399, and an initial derivative liability of $13,399. During the years ended December 31, 2020 and 2019, amortization of the debt discount of $- 0- and $13,399 was charged to interest expense, respectively. During the year ending December 31, 2019, convertible note principal plus their accrued interest totaling $52,514 were converted into 1,239,161 shares of common stock.

On March 27, 2018, the Company completed the closing of a private placement financing transaction (the “Transaction”) when a third-party investor purchased a convertible note (the “Convertible Note”). The Convertible Note carries a 10% annual interest rate and is in the principal amount of $25,000. Principal and interest was due and payable March 27, 2019, and the Note is convertible into shares of the Company’s common stock at any time after one hundred eighty (180) days, at a conversion price (the “Conversion Price”) equal to seventy-five percent (75%) of the average closing price of the Company’s common stock for the ten (10) days immediately preceding the conversion, representing a twenty-five percent (25%) discount. The embedded conversion feature included in the note resulted in an initial debt discount of $6,736, and an initial derivative liability of $6,736. During the year ending December 31, 2019, convertible note principal plus their accrued interest totaling $26,260 were converted into 716,124 shares of common stock.

On May 11, 2018, the Company issued a convertible promissory note (the “Note”), with a face value of $100,000, maturing on May 11, 2019, and stated interest of 10% to a third-party investor. The note is convertible at any time after the funding of the note into a variable number of the Company's common stock, based on a conversion ratio of 62% of the lowest trading price for the 20 days prior to conversion. The note was funded on May 16, 2018, when the Company received proceeds of $75,825, after disbursements to vendors and for the lender’s transaction costs, fees and expenses. The embedded conversion feature included in the note resulted in an initial debt discount of $95,000, an initial derivative expense of $60,635 and an initial derivative liability of $155,635. During the year ended December 31, 2018, the investor converted $50,000 of principal and $1,831 of interest into 5,184,572 shares of common stock. During the year ended December 31, 2019, the investor converted $50,000 of principal and $3,564 of interest into 5,539,273 shares of common stock.

On May 23, 2018, the Company issued a convertible promissory note (the “Note”), with a face value of $60,000, maturing on February 22, 2019, and stated interest of 12% to a third-party investor. The note is convertible at any time after the funding of the note into a variable number of the Company's common stock, based on a conversion ratio of 65% of the lowest trading price for the 20 days prior to conversion. The note was funded on May 30, 2018, when the Company received proceeds of $57,000, after the lender’s transaction costs, fees and expenses. The embedded conversion feature included in the note resulted in an initial debt discount of $57,000, an initial derivative expense of $48,033 and an initial derivative liability of $105,033. During the year ended December 31, 2019, the investor converted $51,275 of principal and $9,838 of interest into 7,909,037 shares of common stock.

On November 2, 2018, the Company issued a convertible redeemable note with a face value of $280,500 (the “Note”), and a back-end convertible redeemable note for $280,000 each. The notes mature on November 2, 2019, and a stated interest of 8% to a third-party investor. The note is convertible at any time after funding of the note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The note was funded on November 2, 2018, when the Company received proceeds of $225,500, after disbursements for the lender’s transaction costs, fees and expenses. The embedded conversion feature included in the note resulted in an initial debt discount of $225,500, an initial derivative expense of $148,544 and an initial derivative liability of $398,544. For the year ended December 31, 2019, amortization of the debt discount of $225,500 was charged to interest expense. The Company also recorded a debt issue discount of $55,500 and amortized $55,500 to interest expense for the year ended December 31, 2019. During the year ending December 31, 2019, an additional penalty of $28,050 was added to the principal of the note due to failure to pay off the note on time. As of December 31, 2020 and 2019, the outstanding note balance is $308,550 and $308,550, respectively. The second note was funded in November of 2018, when the Company received proceeds of $225,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in $55,500 debt issue discount. The embedded conversion feature included in the Note resulted in an initial debt discount of $93,738 and an initial derivative liability of $93,738. During the years ended December 31, 2020 and 2019, amortization of the debt discount of $- 0- and $149,238 was charged to interest expense, respectively. During the year ending December 31, 2019, the Company converted a principal of $280,500 accrued interest of $14,261. As of December 31, 2020 and 2019, the outstanding note balance is $-0- and $-0-, respectively.

F-14

On December 4, 2018, the Company issued a convertible redeemable note (the “Note”) with a face value of $158,333 maturing on December 4, 2019, and a stated interest of 8% to a third-party investor. The note is convertible at any time after funding of the note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The note was funded on December 4, 2018, when the Company received proceeds of $137,500, after disbursements for the lender’s transaction costs, fees and expenses. The embedded conversion feature included in the note resulted in an initial debt discount of $137,500, an initial derivative expense of $87,293 and an initial derivative liability of $224,793. For the year ended December 31, 2019, amortization of the debt discount of $137,500 was charged to interest expense. The Company also recorded a debt issue discount of $20,900 and amortized the full amount to interest expense for the year ended December 31, 2019. During the year ending December 31, 2019, the note holder converted principal amount of $158,333 and accrued interest in the amount of $9,909, resulting in zero balance as of December 31, 2019.

On December 4, 2018, the Company issued to a third-party investor a convertible redeemable note (the “Note”) with a face value of $230,000 and a back-end convertible redeemable note for $230,000. The notes mature on December 4, 2019, have a stated interest of 8% and each note is convertible at any time following the funding of such note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The note was funded on December 4, 2018, when the Company received proceeds of $218,000, after disbursements for the lender’s transaction costs, fees and expenses, resulting in debt issue discount of $12,000. The embedded conversion feature included in the note resulted in an initial debt discount of $218,000, an initial derivative expense of $108,922 and an initial derivative liability of $318,292. For the year ended December 31, 2019, amortization of the debt discount of $218,000 was charged to interest expense. During the year ending December 31, 2019, the Company converted a principal of $225,000 and accrued interest of $14,117. During the year ending December 31, 2020, the Company converted remaining principal of $5,000 and accrued interest of $1,471. As of December 31, 2020 and 2019, the outstanding note balance is $-0- and $5,000 respectively. The second note was funded in December of 2018, when the Company received proceeds of $188,575, after disbursements for the lender's transaction costs, fees, and expenses, resulting in $41,425 debt issue discount. The embedded conversion feature included in the Note resulted in an initial debt discount of $116,600 and an initial derivative liability of $116,600. During the years ended December 31, 2020 and 2019, amortization of the debt discount of $- 0- and $137,500 was charged to interest expense, respectively. During the year ending December 31, 2019, the Company converted a principal of $115,000 accrued interest of $17,388. During the year ending December 31, 2020, the Company converted a principal of $115,000 accrued interest of $14,060. As of December 31, 2020 and 2019, the outstanding note balance is $-0- and $115,000, respectively.

On December 24, 2018, the Company issued to a third-party investor a convertible redeemable note (the “Note”) with a face value of $195,000. The note matures on December 24, 2019, have a stated interest of 8% and each note is convertible at any time following the funding of such note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The note was funded on December 26, 2018, when the Company received proceeds of $160,000, after disbursements for the lender’s transaction costs, fees and expenses, resulting in debt issue discount of $35,000. The embedded conversion feature included in the note resulted in an initial debt discount of $160,000, an initial derivative expense of $92,464 and an initial derivative liability of $269,464. For the year ended December 31, 2019, amortization of the debt discount of $195,000 was charged to interest expense. During the year ending December 31, 2020, the Company converted a principal of $4,150 and accrued interest of $1,521. As of December 31, 2020 and 2019, the outstanding note balance is $190,850 and $195,000 respectively.

On January 22, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $245,000 and two back-end convertible redeemable notes for $122,500 each. The notes mature on January 22, 2020, have a stated interest of 8%. Each Note is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The initial Note was funded on January 22, 2019, when the Company received proceeds of $200,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in $45,000 debt issue discount. The embedded conversion feature included in the Note resulted in an initial debt discount of $200,000, an initial derivative expense of $134,208, and an initial derivative liability of $334,208. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $14,767 and $230,233 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $245,000 and $245,000, respectively. The second note was funded on January 22, 2019, when the Company received proceeds of $100,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in $22,500 debt issue discount. The embedded conversion feature included in the Note resulted in an initial debt discount of $100,000, an initial derivative expense of $77,884, and an initial derivative liability of $177,884. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $7,384 and $115,116 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $122,500 and $122,500, respectively. The third note was funded in July of 2019, when the Company received proceeds of $96,202, after disbursements for the lender's transaction costs, fees, and expenses, resulting in $22,500 debt issue discount. The embedded conversion feature included in the Note resulted in an initial debt discount of $96,202 and an initial derivative liability of $96,202. During the years ended December 31, 2020 and 2019, amortization of the debt discount of $7,155 and $111,547 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $122,500 and $122,500, respectively

On February 22, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $116,667. The Note matures on February 22, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on February 22, 2019, when the Company received proceeds of $90,000 after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $26,667. The embedded conversion feature included in the Note resulted in an initial debt discount of $90,000, an initial derivative expense of $36,138, and an initial derivative liability of $126,138. During the years ended December 31, 2020 and 2019, amortization of the debt discount of $16,941 and $99,726 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $38,917 and $38,917, respectively.

F-15

On March 8, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $133,333. The Note matures on March 8, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on March 8, 2019, when the Company received proceeds of $106,200, after disbursements for the lender's transaction costs, fees, and expenses. The embedded conversion feature included in the Note resulted in an initial debt discount of $106,200, debt issues discount of $27,133, an initial derivative expense of $82,538, and an initial derivative liability of $188,738. During the years ended December 31, 2020 and 2019, amortization of the debt discount of $24,772 and $108,561 was charged to interest expense, respectively. During the year ending December 31, 2020, the Company converted a principal of $133,333 and accrued interest of $20,900. As of December 31, 2020 and 2019, the outstanding note balance is $-0- and $133,333, respectively.

On March 20, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $89,085 and a back-end convertible redeemable note for $89,085. The notes mature on March 20, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The initial Note was funded on March 20, 2019, when the Company received proceeds of $75,000 after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $14,085. The embedded conversion feature included in the Note resulted in an initial debt discount of $75,000, an initial derivative expense of $48,913, and an initial derivative liability of $123,913. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $19,472 and $69,613 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $-0- and $133,333, respectively. The second note was funded on March 20, 2019, when the Company received proceeds of $75,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in $14,085 debt issue discount. The embedded conversion feature included in the Note resulted in an initial debt discount of $75,000, an initial derivative expense of $66,439, and an initial derivative liability of $141,439. During the years ended December 31, 2020 and 2019, amortization of the debt discount of $19,472 and $69,613 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $89,085 and $89,085, respectively.

Also, on March 20, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $89,085 and a back-end convertible redeemable note for $89,085. The notes mature on March 20, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The initial Note was funded on March 20, 2019, when the Company received proceeds of $75,000 after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $14,085. The embedded conversion feature included in the Note resulted in an initial debt discount of $75,000, an initial derivative expense of $48,913, and an initial derivative liability of $123,913. During the years ended December 31, 2020 and 2019, amortization of the debt discount of $19,472 and $69,613 was charged to interest expense, respectively. During the year ending December 31, 2020, a penalty of $16,517 was added to the principal balance due to failure to pay off the note on time. During the year ending December 31, 2020, the Company converted a principal of $6,500 and accrued interest of $549. As of December 31, 2020 and 2019, the outstanding note balance is $99,102 and $89,085, respectively. The second note was funded on March 20, 2019, when the Company received proceeds of $75,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in $14,085 debt issue discount. The embedded conversion feature included in the Note resulted in an initial debt discount of $75,000, an initial derivative expense of $66,439, and an initial derivative liability of $141,439. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $19,472 and $69,613 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $89,085 and $89,085, respectively.

On April 12, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $208,000. The Note matures on April 12, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on April 12, 2019, when the Company received proceeds of $175,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $33,000. The embedded conversion feature included in the Note resulted in an initial debt discount of $175,000, an initial derivative expense of $104,450, and an initial derivative liability of $279,450. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $58,536 and $149,464 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $208,000 and $208,000, respectively.

Also, on April 12, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $208,000. The Note matures on April 12, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on April 12, 2019, when the Company received proceeds of $175,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $33,000. The embedded conversion feature included in the Note resulted in an initial debt discount of $175,000, an initial derivative expense of $104,450, and an initial derivative liability of $279,450. During the year ending December 31, 2020, a penalty of $41,600 was added to the principal balance due to failure to pay off the note on time. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $58,536 and $149,464 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $249,600 and $208,000, respectively.

On May 15, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $208,000. The Note matures on May 15, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on May 15, 2019, when the Company received proceeds of $175,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $33,000. The embedded conversion feature included in the Note resulted in an initial debt discount of $175,000, an initial derivative expense of $104,082, and an initial derivative liability of $279,082. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $77,290 and $130,710 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $208,000 and $208,000, respectively.

F-16

Also, on May 15, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $167,352. The Note matures on May 15, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on May 15, 2019, when the Company received proceeds of $140,250, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $27,102. The embedded conversion feature included in the Note resulted in an initial debt discount of $140,250, an initial derivative expense of $85,329, and an initial derivative liability of $225,579. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $62,185 and $105,167 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $167,352 and $167,352, respectively.

On June 13, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $119,000. The Note matures on June 13, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on June 13, 2019, when the Company received proceeds of $100,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $19,000. The embedded conversion feature included in the Note resulted in an initial debt discount of $100,000, an initial derivative expense of $49,779, and an initial derivative liability of $149,779. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $53,648 and $65,352 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $119,000 and $119,000, respectively.

Also, on June 13, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $119,000. The Note matures on June 13, 2020, has a stated interest of 8%, and convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on June 13, 2019, when the Company received proceeds of $100,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $19,000. The embedded conversion feature included in the Note resulted in an initial debt discount of $100,000, an initial derivative expense of $49,779, and an initial derivative liability of $149,779. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $53,648 and $105,167 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $119,000 and $119,000, respectively.

On July 1, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $183,975. The Note matures on July 1, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on July 1, 2019, when the Company received proceeds of $150,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $33,975. The embedded conversion feature included in the Note resulted in an initial debt discount of $150,000, an initial derivative expense of $65,783, and an initial derivative liability of $215,783. During the year ending December 31, 2020, the Company converted a principal of $121,475and accrued interest of $6,376. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $91,988 and $91,988 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $62,500 and $183,975, respectively.

On August 9, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $122,650. The Note matures on August 9, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on August 9, 2019, when the Company received proceeds of $100,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $11,150. The embedded conversion feature included in the Note resulted in an initial debt discount of $100,000, an initial derivative expense of $18,522, and an initial derivative liability of $118,522. . During the year ended December 31, 2020 and 2019, amortization of the debt discount of $79,255 and $43,395 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $122,650 and $122,650, respectively.

On September 12, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $160,000. The Note matures on September 12, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on September 12, 2019, when the Company received proceeds of $130,050, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $29,950. The embedded conversion feature included in the Note resulted in an initial debt discount of $130,050, an initial derivative expense of $25,433, and an initial derivative liability of $155,483. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $111,913 and $48,087 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $160,000 and $160,000, respectively.

F-17

On October 3, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $75,000. The Note matures on October 3, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on October 3, 2019, when the Company received proceeds of $60,645, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $14,355. The embedded conversion feature included in the Note resulted in an initial debt discount of $60.645, an initial derivative expense of $74,404, and an initial derivative liability of $135,049. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $56,762 and $18 238 was charged to interest expense, respectively. During the year ending December 31, 2020, the Company converted a principal of $21,250. As of December 31, 2020 and 2019, the outstanding note balance is $53,750 and $75,000, respectively.

On November 1, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $100,000. The Note matures on November 1, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on November 1, 2019, when the Company received proceeds of $79,650, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $20,350. The embedded conversion feature included in the Note resulted in an initial debt discount of $79,650, an initial derivative expense of $50,171, and an initial derivative liability of $129,821. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $79,781and $20,219 was charged to interest expense, respectively. As of December 31, 2020 and 2019, the outstanding note balance is $100,000 and $100,000, respectively.

On November 1, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $56,000. The Note matures on November 1, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on November 1, 2019, when the Company received proceeds of $50,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $6,000. The embedded conversion feature included in the Note resulted in an initial debt discount of $50,000, an initial derivative expense of $17,328, and an initial derivative liability of $67,328. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $46,820 and $9,180 was charged to interest expense, respectively. During the year ending December 31, 2020, the Company converted a principal of $9,256. As of December 31, 2020 and 2019, the outstanding note balance is $46,744 and $100,000, respectively.

On December 24, 2019, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $33,000. The Note matures on November 1, 2020, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on December 24, 2019, when the Company received proceeds of $30,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $3,000. The embedded conversion feature included in the Note resulted in an initial debt discount of $30,000, an initial derivative expense of $9,670, and an initial derivative liability of $39,670. During the year ended December 31, 2020 and 2019, amortization of the debt discount of $32,369 and $631 was charged to interest expense, respectively. of December 31, 2020 and 2019, the outstanding note balance is $33,000 and $33,000, respectively.

On January 23, 2020, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $22,000. The Note matures on January 23, 2021, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on January 23, 2020, when the Company received proceeds of $20,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $2,000. The embedded conversion feature included in the Note resulted in an initial debt discount of $20,000, an initial derivative expense of $15,101, and an initial derivative liability of $35,101. During the year ended December 31, 2020, amortization of the debt discount of $20,617 was charged to interest expense, respectively. As of December 31, 2020, the outstanding note balance is $22,000.

On January 30, 2020, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $60,000. The Note matures on January 30, 2021, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on January 30, 2020, when the Company received proceeds of $50,000, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $10,000. The embedded conversion feature included in the Note resulted in an initial debt discount of $50,000, an initial derivative expense of $73,171, and an initial derivative liability of $123,171. During the year ended December 31, 2020, amortization of the debt discount of $55,082 was charged to interest expense, respectively. As of December 31, 2020, the outstanding note balance is $60,000.

F-18

On March 12, 2020, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $100,000. The Note matures on March 12, 2021, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on March 12, 2020, when the Company received proceeds of $79,650, after disbursements for the lender's transaction costs, fees, and expenses, resulting in debt issue discount of $20,350. The embedded conversion feature included in the Note resulted in an initial debt discount of $79,650, an initial derivative expense of $51,707, and an initial derivative liability of $131,357. During the year ended December 31, 2020, amortization of the debt discount of $111,905 was charged to interest expense, respectively. As of December 31, 2020, the outstanding note balance is $100,000.

A summary of the convertible note balances as of December 31, 2020, and 2019, is as follows:

	December 31, 2020			December 31, 2019
Principal balance	$	i 3,286,270		$	i 3,402,117
Unamortized discounts		( i 30,672	)		( i 1,011,636	)
Ending balance, net	$	i 3,255,598		$	i 2,390,481

All convertible notes are due within 12 months and classified as a short-term liability on the balance sheet.

NOTE 10 – DERIVATIVE LIABILITIES

The Company determined that the conversion features of the convertible notes represented embedded derivatives since the Notes are convertible into a variable number of shares upon conversion. Accordingly, the notes are not considered to be conventional debt under EITF 00-19 and the embedded conversion feature is bifurcated from the debt host and accounted for as a derivative liability. Accordingly, the fair value of these derivative instruments is recorded as liabilities on the consolidated balance sheet with the corresponding amount recorded as a discount to each Note, with any excess of the fair value of the derivative component over the face amount of the note recorded as an expense on the issue date. Such discounts are amortized from the date of issuance to the maturity dates of the Notes. The change in the fair value of the derivative liabilities are recorded in other income or expenses in the condensed consolidated statements of operations at the end of each period, with the offset to the derivative liabilities on the balance sheet.

The Company valued the derivative liabilities at issuance, December 31, 2020, and December 31, 2019, at $412,801 and $4,745,194, respectively. The Company used the multinomial lattice valuation model with the following assumptions for new notes issued during the year ended December 31, 2020, risk-free interest rate of 0.05% and volatility of 150% to 250%, and as of December 31, 2019, risk-free interest rate of 0.05% and volatility of 200% to 300%.

A summary of the activity related to derivative liabilities during the year ended December 31, 2020, and 2019, is as follows:

	December 31, 2020			December 31, 2019
Beginning Balance	$	i 3,515,055		$	i 1,807,404
Initial derivative liability		i 412,801			i 4,745,194
Fair value change		i 1,198,529			( i 942,398	)
Reclassification for principal payments and conversions		( i 1,079,984	)		( i 2,095,145	)
Ending Balance	$	i 4,046,401		$	i 3,515,055

Derivative liability expense of $1,016,050 for the year ended December 31, 2020, consisted of the initial derivative expense of $213,151 and the above loss on changes in fair value of $802,900. Derivative liability expense of $540,678 for the year ended December 31, 2019, consisted of the initial derivative expense of $1,734,337 and the above gain on change in fair value of $1,736,559.

NOTE 11– COMMITMENTS AND CONTINGENCIES

Lease Agreements

On September 10, 2018, pursuant to the Amos Audiology acquisition, the Company assumed a lease dated December 1, 2017 and expiring April 30, 2023, in Walnut Creek, California. Lease payments in the first year of the lease are $3, 988 per month and increase by 3% on December 1 each new lease year. As of December 31, 2018, the Company was in arrears of $25,182 (including late fees) in lease payments and has agreed with the landlord to pay the arrears in seven monthly payments of $3,597 in addition to the monthly lease payments for January 2019 through July 2019. Settlement fees were fully paid during the year ending December 31, 2019.

F-19

On October 15, 2018, the Company entered into a lease to operate a retail hearing aid clinic in Roseville, California expiring December 31, 2023. Initial lease payments of $3,102 began on January 1, 2019, and increase by 3% on January 1 each new lease year. Upon adoption of ASC 842, the Company recognized $160,623 of right-to-use assets as operating leases and operating lease obligations. The Company abandoned the lease location in November of 2020, therefore, a ROU asset loss was recognized in the amount of $106,419 during year ending December 31, 2020. No changes to operating lease liability have been made until the settlement has been reached.

On November 18, 2019, the Company entered into a lease to operate a retail hearing aid clinic in Walnut Creek, expiring in October of 2022. Initial lease payments of $3,930 began on December 1, 2019, and increase by 3% on December 1 each new lease year. Upon adoption of ASC 842, the Company recognized $129,281 of right-to-use assets as operating leases and operating lease obligations. The Company abandoned the lease location in April of 2021.

On December 1, 2018, the Company entered into a lease to operate a retail hearing aid clinic in Sacramento, California expiring March 31, 2024. Initial lease payments of $3,002 began on April 1, 2019, and increase by 3.33% on April 1, 2020 and 2021, and by 3% on April 1, 2022. Upon adoption of ASC 842, the Company recognized $149,507 of right-to-use assets as operating leases and operating lease obligations. The Company abandoned the lease location in November of 2020, therefore, a ROU asset loss was recognized in the amount of $102,312 during year ending December 31, 2020. No changes to operating lease liability have been made until the settlement has been reached. Subsequent to year ending December 31, 2020, the Company reached the settlement where the Company agreed to make either one time payment of $44,000 or make fourteen monthly payments of $3,220.

On April 15, 2019, the Company entered into a lease to operate a retail hearing aid clinic in Pleasanton, California expiring April of 2024. Initial lease payments of $3,551 began on May 1, 2019, and increase by 3% on May 1 each new lease year. Upon adoption of ASC 842, the Company recognized $185,068 of right-to-use assets as operating leases and operating lease obligations. The Company abandoned the lease location in December of 2019, therefore, a ROU asset loss was recognized in the amount of $153,589 during year ending December 31, 2019. No changes to operating lease liability have been made until the settlement has been reached.

On February 1, 2019, the Company entered into a lease to operate a retail hearing aid clinic in Fremont, California expiring February 28, 2021. Initial lease payments of $2,019 began on March 1, 2019, and increases by 3% on March 1, 2020. The Company terminated the lease in 2019 and agreed to make a payment of $4,038 in order to settle the lease.

On June 1, 2019, the Company entered into a lease to operate a retail hearing aid clinic in Hayward, California expiring June of 2021. Initial lease payments of $1,816 began on June 1, 2019, and increase by 3% on June 1 each new lease year. Upon adoption of ASC 842, the Company recognized $34,486 of right-to-use assets as operating leases and operating lease obligations. The Company abandoned the lease location in December of 2019, therefore, a ROU asset loss was recognized in the amount of $14,348 during year ending December 31, 2019. No changes to operating lease liability have been made until the settlement has been reached.

The operating lease expense for the year ending December 31, 2020 and 2019 was $322,879 and $424,613, respectively. These leases will expire between 2021 and 2023. The weighted average discount rate used for these leases were 8% (average borrowing rate of the Company). Future principal payments for the Company’s portion are:

For the twelve months ending December 31,	Amount
2021	$	i 360,815
2022		i 156,548
2023		i 89,208
2024		—
Thereafter		—
Total	$	i 606,571

F-20

Consulting Agreements

On October 3, 2018, the Company entered into a Manufacturing Design and Marketing Agreement (the “Agreement”) with Zounds, whereby, Zounds will provide design, technology, manufacturing and supply chain services to the Company, to enable the Company to manufacture comparable hearing aids and related components and accessories to be sold under the Company’s exclusive brand names (the “Manufacturer’s Products”) through the Company’s various marketing and distribution channels. The Company will pay Zounds One Million ($1,000,000) (the “Technology Access Fee”). The Technology Access Fee, as amended will be paid in eight (8) installments of $75,000 each, in four- week intervals until $600,000 is paid and $400,000 is to be paid as Product Surcharges based on $200 per unit manufactured for up to the first 2,000 units. Once $400,000 of Product Surcharges are paid said per unit surcharge will be discontinued. As of December 31, 2018, the Company has paid $183,200 towards the Technology Access Fee and as of December 31, 2018, $816,800 is included in accounts payable and accrued expenses. During the year ended December 31, 2020, the Company determined that it was unable to substantiate the actual fair value of the technology that was acquired so has chosen to impair the full amount (Note 4).

NOTE 12– INCOME TAXES

The Tax Cuts and Jobs Act (the “Act”) enacted on December 22, 2017 reduces the US federal corporate tax rate from 35% to 21% and requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and creates new taxes on certain foreign sourced earnings. As of December 31, 2020, the Company has not completed the accounting for the tax effects of enactment of the Act; however, as described below, it has made a reasonable estimate of the effects on existing deferred tax balances. These amounts are provisional and subject to change.

The provision for income taxes is calculated at US corporate tax rate of approximately 21% (2019: 21%) as follows:

	2020			2019
Expected income tax recovery from net loss	$	i 1,040,275		$	i 1,663,974
Tax effect of expenses not deductible for income tax:
Annual effect of book/tax difference		( i 523,142	)		( i 890,866	)
Change in valuation allowance		( i 517,133	)		( i 773,108	)
		—			—

Deferred tax assets

Deferred taxes are provided on a liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Net deferred tax assets consist of the following components as of December 31:

	2020			2019
Tax effect of NOL carryover	$	i 2,594,396		$	i 2,077,264
Less valuation allowance		( i 2,594,396	)		( i 2,077,264	)
		—			—

At December 31, 2020, the Company performed a comprehensive analysis of its tax estimates and revised comparative figures accordingly, which had no net impact on deferred tax recorded. The Company had net operating loss carry forwards of approximately $2,594,396 (2019: $2,077,264) that may be offset against future taxable income from the year by 2040. No tax benefit has been reported in the December 31, 2020 and 2019 consolidated financial statements since the potential tax benefit is offset by a valuation allowance of the same amount. The Company is taxed in the United States at the Federal level. All tax years since inception are open to examination because no tax returns have been filed.

F-21

NOTE 13 – STOCKHOLDERS’ EQUITY

Preferred Stock

The Company has 25,000,000 authorized shares of $0.0001 preferred stock.

Series A Preferred Stock

On June 4, 2018, the Company filed in the State of Nevada a Certificate of Designation of a series of preferred stock, the Series A Preferred Stock. 9,510,000 shares were designated as Series A Preferred Stock. The Series A Preferred Stock has mandatory conversion rights, whereby each share of Series A Preferred Stock will convert two (2) shares of common stock upon the Company filing Amended and Restated Articles of Incorporation with the Secretary of State of Nevada, increasing the authorized shares of common stock. The Series A Preferred Stock has voting rights on an is if converted basis. The Series A Preferred Stock does not have any right to dividends. On June 4, 2018 the Company issued 3,170,000 shares of Series A Preferred Stock each to Matthew, Mark and Kimberly, in exchange for each of them cancelling and returning to treasury 6,340,000 shares of common stock. The issuances were made in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act, and Rule 506(b) promulgated thereunder, as the shareholders are accredited investors, there was no general solicitation, and the transaction did not involve a public offering. On August 8, 2018, Matthew, Mark and Kim each converted 3,170,000 shares of Series A Preferred Stock for 6,340,000 shares of common stock each. The common stock issued replaced the 19,020,000 shares in the aggregate that the Moore’s cancelled in June 2018. As of December 31, 2020 and 2019, there were no shares of Series A Preferred Stock issued and outstanding.

Series B Preferred Stock

On June 4, 2018, the Company also filed in the State of Nevada a Certificate of Designation of a series of preferred stock, the Series B Preferred Stock. 900,000 shares were designated as Series B Preferred Stock. The Series B Preferred Stock is not convertible into common stock, nor does the Series B Preferred Stock have any right to dividends and any liquidation preference. The Series B Preferred Stock entitles its holder to a number of votes per share equal to 1,000 votes. On June 4, 2018, the Company issued 300,000 shares of its Series B Preferred Stock each to Matthew, Mark and Kimberly, in consideration of $45,000 of accrued expenses, the Company’s failure to timely pay current and past salaries, and the willingness to accrue unpaid payroll and non-reimbursement of business expenses without penalty or action for all amounts. The issuances were made in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act, and Rule 506(b) promulgated thereunder, as the shareholders are accredited investors, there was no general solicitation, and the transaction did not involve a public offering. The Company determined that fair value of the Series B Preferred Stock issued to the Company’s CEO was $817,600. The fair value was determined as set forth in the Statement of Financial Accounting Standard ASC 820-10-35-37, Fair Value in Financial Instruments. As of December 31, 2020 and 2019, there were 900,000 shares of Series B Preferred Stock issued and outstanding.

Common Stock

The Company has 490,000,000 authorized shares of $0.0001 common stock. On January 30, 2020, the Company increased a number of authorized common shares to 14,975,000,000. As of December 31, 2020, and December 31, 2019, there are 3,628,422,041 and 342,118,135, respectively, shares of common stock outstanding.

During the year ending December 31, 2019, the Company issued 209,116,478 shares of common stock for partial conversion of principal and accrued interest.

During the year ending December 31, 2019, Company’s management made a contribution of $12,048. No shares have been issued.

During the year ending December 31, 2020, the Company issued 3,286,303,906 shares of common stock for partial conversion of principal and accrued interest.

Common Stock to be issued

As of December 31, 2018, the Company recorded 1,838,564 shares of common stock to be issued for the conversion of $100,000 of principal and $2,456 of accrued interest, for a total of $102,456. Shares have been issued during year ending December 31, 2019.

On October 13, 2018, the Company recorded 1,000,000 shares of restricted common stock to be issued to Erchonia.

On December 7, 2018, the Company recorded 3,125,000 shares of common stock to be issued pursuant to the Media Consulting Agreement. 1,712,329 of common shares have been issued during the year ending December 31, 2019.

On December 31, 2018, the Company recorded 410,284 shares of common stock to be issued pursuant to the CSMA. Shares have been issued during year ending December 31, 2019.

As of December 31, 2020 and 2019, there are 2,415,671 shares of common stock to be issued.

F-22

NOTE 14 – RISKS AND UNCERTAINTIES

The Company's business and operations are sensitive to general business and economic conditions in the United States. A host of factors beyond the Company's control could cause fluctuations in these conditions. Adverse conditions may include recession, downturn or otherwise, local competition or changes in consumer taste. These adverse conditions could affect the Company's financial condition and the results of its operations.

In December 2020, a novel strain of coronavirus (COVID-19) was reported in Wuhan, China and has spread throughout the United States and the rest of the world. The World Health Organization has declared the outbreak to constitute a “Public Health Emergency of International Concern.” This contagious disease outbreak, which has not been contained, and is disrupting supply chains and affecting production and sales across a range of industries in United States and other companies as a result of quarantines, facility closures, and travel and logistics restrictions in connection with the outbreak, as well as the worldwide adverse effect to workforces, economies, and financial markets, leading to a global economic downturn. As a result, the Company experienced a negative impact to its operating results. Regarding future operations, the related financial impact and duration cannot be reasonably estimated at this time.

NOTE 15 – BUSINESS ACQUISITION

ASC Topic 805, "Business Combinations," requires that all business combinations be accounted for using the acquisition method and that certain identifiable intangible assets acquired in a business combination be recognized as assets apart from goodwill. ASC Topic 350, "Intangibles-Goodwill and Other" ("ASC 350"), requires goodwill and other identifiable intangible assets with indefinite useful lives not to be amortized, such as trade names, but instead tested at least annually for impairment and be written down if impaired. ASC 350 requires that goodwill be allocated to its respective reporting unit and that identifiable intangible assets with finite lives be amortized over their useful lives.

On November 22, 2021, the Company purchased Hearing Assist II, LLC. The Company acquired 100% interest in the entity for a total consideration of 591,209,963 common shares valued at $8,513,423 on the day of purchase. As part of the acquisition, the Company assumed assets in the amount of $15,713,000, consisting of trademarks, domains, customer lists, customer contracts, licenses, royalties, other contracts, and assumed liabilities in the amount of $7,199,678. This acquisition was accounted for using the acquisition method of accounting. The fair value of assets, liabilities and intangible assets and the purchase price allocation as of November 22, 2021 was as follows:

	Allocation of Purchase Price
	$
Assets
Cash		i 44,850
Accounts Receivable		i 789,009
Inventory		i 2,243,947
Other assets		i 83,163
Property and equipment		i 93,632
Total assets		i 3,254,601

Liabilities
Accounts payable		i 4,303,622
Accrued expenses and other current liabilities		i 2,460,785
Other current liabilities		i 2,659,855
Long-term liabilities		i 1,560,510
Total liabilities		i 10,984,772
Net liabilities		( i 7,730,171	)
Intangible Asset: Hearing Aid		i 3,000,000
Intangible Asset: Customer Database		i 7,374,450
Intangible Asset: Loyalties		i 5,338,550
Goodwill		i 530,594
Total net assets acquired		i 8,513,423

The purchase consideration of 591,209,963 of the Company’s common stock valued as detailed below:

Number of Common Stock		591,209,963
Market price on the date of issuance		i 0.0144
Purchase consideration	$	i 8,513,423

The following unaudited pro forma consolidated statements of operations for the years ended December 31, 2020 present the Company’s results of operations as adjusted to give effect to the FYE 2021 Transaction as if it had occurred at the beginning of the period. The accompanying unaudited pro forma consolidated balance sheet as of December 31, 2020 presents the Company’s financial position as if the FYE Transaction had occurred on December 31, 2020.

F-23

The unaudited pro forma information below is provided for information purposes only and is not necessarily indicative of what the actual financial position or results of operations of the Company would have been had the transaction actually occurred on the dates indicated, nor does it purport to indicate the future financial position or results of operations of the Company. The pro forma adjustments are based upon available information and assumptions believed to be reasonable in the circumstances. There can be no assurance that such information and assumptions will not change from those reflected in the unaudited pro forma condensed financial statements and notes thereto.

INNERSCOPE HEARING TECHNOLOGIES, INC.

PRO FORMA CONSOLIDATED BALANCE SHEETS (Unaudited)

Historical InnerScope Hearing Technologies, Inc.

Acquisition

Pro forma combined

As of December 31, 2020

of Hearing Assist II, LLC

Pro forma adjustments

As of December 31, 2020

ASSETS

Current Assets:

Cash

i 3,349

i 177,834

—

i 181,183

Accounts receivable, allowance for doubtful accounts

i 12,429

i 1,832,042

—

i 1,844,471

Employee advances

i 3,000

—

i 3,000

Prepaid assets

—

i 103,190

—

i 103,190

Inventory

i 4,671

i 2,242,409

—

i 2,247,080

Total current assets

i 23,450

i 4,355,475

—

i 4,378,925

—

Security deposits

i 4,863

—

i 4,863

Domain name

i 3,000

—

i 3,000

Other assets

—

i 63,260

Intangible assets, net of accumulated amortization

—

(a)

i 4,410,947

Property and equipment, net of accumulated depreciation

i 60,203

i 78,977

—

i 139,180

Operating leases right-of-use assets, net

i 364,062

—

i 364,062

Investment in undivided interest in real estate

i 1,227,733

—

i 1,227,733

Total assets

i 1,683,311

i 4,497,712

i 4,410,947

i 10,591,970

LIABILITIES AND STOCKHOLDERS' DEFICIT

Current Liabilities:

Bank overdraft

i 269

—

i 269

Accounts payable and accrued expenses

i 1,841,302

i 5,828,561

—

i 7,669,863

Accounts payable to related party

i 662,178

—

i 662,178

Notes payable - stockholder

i 95,800

—

i 95,800

Current portion of convertible notes payable, net of discounts

i 3,255,598

—

i 3,255,598

Note payable, other & related party

i 118,786

—

i 118,786

Customer deposits

i 10,925

—

i 10,925

Other current liabilities

—

Current portion of note payable- undivided interest in real estate

i 22,150

—

i 22,150

Derivative liabilities

i 4,046,401

—

i 4,046,401

Operating lease liabilities, current portion

i 365,587

—

i 365,587

Total current liabilities

i 10,418,996

i 5,828,561

—

i 16,247,557

EIDL loan

—

i 150,000

—

i 150,000

Long term portion of note payable- undivided interest in real estate

i 938,003

—

i 938,003

PPP loan

i 262,445

—

i 262,445

Other long-term liabilities

i 11,528

—

i 11,528

Long-term loan

—

i 1,844,020

—

i 1,844,020

Operating lease liabilities, Less current portion

i 416,788

—

i 416,788

Total liabilities

i 12,036,232

i 7,834,109

—

i 19,870,341

Commitments and contingencies

Stockholders' Deficit:

Members' Capital

—

i 4,112,476

(a)

( i 4,112,476

)

—

Preferred stock, $0.0001 par value; 25,000,000 shares authorized;

Series A preferred stock, par value $0.0001, -0- (2020)

i 90

—

i 90

Series B preferred stock, par value $0.0001, 900,000 (2020) shares authorized, and 900,000 (2020) shares issued and outstanding

—

Common stock, $0.0001 par value; 14,975,000,000 (2020) shares authorized and 3,628,422,042 (2020) shares issued and outstanding

i 362,846

i —

(a)

i 59,121

i 421,967

Common stock to be issued, $0.0001 par value, 2,412,671 (2020) shares

i 242

—

i 242

Additional paid-in capital

i 8,534,062

—

(a)

i 8,454,302

i 16,988,364

Accumulated deficit

( i 19,250,161

)

( i 7,448,873

)

—

( i 26,699,034

)

Total stockholders' deficit

( i 10,352,921

)

( i 3,336,397

)

i 4,400,947

( i 9,288,371

)

Total Liabilities and Shareholder Equity

i 1,683,311

i 4,497,712

i 4,400,947

i 10,581,970

F-24

INNERSCOPE HEARING TECHNOLOGIES, INC.

PRO FORMA CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

Historical InnerScope Hearing Technologies, Inc.

Acquisition

Pro forma combined

As of December 31, 2020

of Hearing Assist II, LLC

Pro forma adjustments

As of December 31, 2020

Revenues:

Revenues, other

i 166,111

i 15,753,402

—

i 15,919,513

Total revenues

i 166,111

i 15,753,402

—

i 15,919,513

Cost of sales

Cost of sales, other

i 68,768

i 7,781,088

—

i 7,849,856

Total cost of sales

i 68,768

i 7,781,088

—

i 7,849,856

—

Gross profit

i 97,343

i 7,972,314

—

i 8,069,657

Operating Expenses:

Compensation and benefits

i 661,840

i 383,625

—

i 1,045,465

Advertising and promotion

i 19,762

i 6,893,439

—

i 6,913,201

R&D expense

i 276,926

—

i 276,926

Professional fees

i 114,476

i 193,168

—

i 307,644

Rent, including related party

i 322,879

i 129

—

i 323,008

Investor relations

i 14,796

—

i 14,796

Depreciation and Amortization expense

i 123,646

i 109,695

—

i 233,341

Other general and administrative

i 69,188

i 765,795

—

i 834,983

Total operating expenses

i 1,326,585

i 8,622,777

—

i 9,949,362

Loss from operations

( i 1,229,243

)

( i 650,463

)

—

( i 1,879,706

)

Other Income (Expense):

Other income

Derivative income (loss)

( i 1,066,904

)

—

( i 1,066,904

)

Gain (loss) on equity investment

i 30,646

i 6,889

—

i 37,535

Amortization of debt discount

( i 1,222,965

)

—

( i 1,222,965

)

Gain/Loss on debt extinguishment

—

i 6,000

—

i 6,000

Gain/Loss on lease termination

( i 201,283

)

—

( i 201,283

)

Other income (expenses)

i 181

—

i 181

Loss on intangibles

( i 775,000

)

—

( i 775,000

)

Gain/Loss on assets disposal

—

( i 59,093

)

—

( i 59,093

)

Interest expense and finance charges

( i 489,123

)

( i 448,678

)

—

( i 937,801

)

Total other income (expense), net

( i 3,724,447

)

( i 494,882

)

—

( i 4,219,329

)

Loss before income tax

( i 4,953,690

)

( i 1,145,345

)

—

( i 6,099,035

)

—

Income tax provision

—

Net Loss

( i 4,953,690

)

( i 1,145,345

)

—

( i 6,099,035

)

Basic and diluted income (loss) per share

( i 0.00

)

( i 0.00

)

Weighted average number of common shares outstanding

Basic and diluted

i 2,769,472,382

The unaudited pro forma consolidated financial statements give effect to the following adjustment:

Adjustments to eliminate Hearing Assist II, LLC members’ capital and record issuance of an aggregate of approximately 591,209,963 shares of InnerScope common stock to the Hearing Assist II, LLC members, par value $0.001, in exchange for 100% of equity interests of Hearing Assist II, LLC held by the Hearing Assist II, LLC members in accordance with the Exchange Agreement dated November 22, 2021.

F-25

NOTE 16 – SUBSEQUENT EVENTS

From January 1, 2021, through June 30, 2022, the Company received conversion notices for the issuance of 2,856,563,078 shares of common stock for conversion of $3,315,409 of principal and $992,743 of accrued interest on convertible notes.

From January 1, 2021, through June 30, 2022, the Company issued 52,124,378 as part of compensation for services based on the market price of the common stock on the date the Company agreed to issue the shares.

From January 1, 2021, through June 30, 2022, the Company issued 65,000,000 for cash for a total value of $650,000.

From January 1, 2021, through June 30, 2022, the Company issued 127,653,805 to settle payables in the amount of $651,034.

On February 5, 2021, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $195,000. The Note matures on February 5, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on February 5, 2021, when the Company received proceeds of $176,000 after disbursements for the lender's transaction costs, fees, and expenses.

On February 25, 2021, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $165,000. The Note matures on February 25, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on February 25, 2021, when the Company received proceeds of $155,000 after disbursements for the lender's transaction costs, fees, and expenses.

On April 6, 2021, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $165,000. The Note matures on April 6, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on April 6, 2021, when the Company received proceeds of $155,000 after disbursements for the lender's transaction costs, fees, and expenses.

On July 7, 2021, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $165,000. The Note matures on July 6, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on July 7, 2021, when the Company received proceeds of $155,000 after disbursements for the lender's transaction costs, fees, and expenses.

On August 25, 2021, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $165,000. The Note matures on August 25, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on August 25, 2021, when the Company received proceeds of $155,000 after disbursements for the lender's transaction costs, fees, and expenses.

On September 20, 2021, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $165,000. The Note matures on September 20, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on October 13, 2021, when the Company received proceeds of $155,000 after disbursements for the lender's transaction costs, fees, and expenses.

On October 13, 2021, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $330,000. The Note matures on October 13, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on October 13, 2021, when the Company received proceeds of $310,000 after disbursements for the lender's transaction costs, fees, and expenses.

On November 9, 2021, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $266,000. The Note matures on November 9, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on November 9, 2021, when the Company received proceeds of $250,000 after disbursements for the lender's transaction costs, fees, and expenses.

On November 15, 2021, the Company sold 30 million shares for aggregate proceeds of $300,000, of which a portion of the proceeds was utilized to pay principal and interest on an outstanding convertible loan in the aggregate amount of approximately $70,000.

On December 21, 2021, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $266,000. The Note matures on December 21, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on December 21, 2021, when the Company received proceeds of $200,000 after disbursements for the lender's transaction costs, fees, and expenses.

F-26

On January 13, 2022, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $158,000. The Note matures on January 13, 2023, has a stated interest of 8%, and is convertible at any time following the funding of such Note into a variable number of the Company's common stock, based on a conversion ratio of 70% of the lowest closing bid price for the 15 days prior to conversion. The Note was funded on January 13, 2021, when the Company received proceeds of $150,000 after disbursements for the lender's transaction costs, fees, and expenses. The loan was fully forgiven during period end March 31, 2022.

On January 28, 2022, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $262,000. The Note matures October 28, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note at a set price of $0.01 per shares. The Note was funded on January 28, 2022, when the Company received proceeds of $250,000 after disbursements for the lender's transaction costs, fees, and expenses.

On February 28, 2022, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $262,000. The Note matures November 18, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note at a set price of $0.01 per shares. The Note was funded on February 28, 2022,, when the Company received proceeds of $250,000 after disbursements for the lender's transaction costs, fees, and expenses.

On March 11, 2022, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $262,000. The Note matures December 11, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note at a set price of $0.01 per shares. The Note was funded on March 11, 2022, when the Company received proceeds of $250,000 after disbursements for the lender's transaction costs, fees, and expenses.

On March 30, 2022, the Company issued to a third-party investor a convertible redeemable note (the "Note") with a face value of $262,000. The Note matures December 31, 2022, has a stated interest of 8%, and is convertible at any time following the funding of such Note at a set price of $0.01 per shares. The Note was funded on March 30, 2022, when the Company received proceeds of $250,000 after disbursements for the lender's transaction costs, fees, and expenses.

On April 29, 2022, the Company issued to a third-party investor a conventional note payable(the "Note") with a face value of $262,000. The Note matures April 29, 2023, has a stated interest of 8% The Note was funded on April 29, 2022, when the Company received proceeds of $262,000 after disbursements for the lender's transaction costs, fees, and expenses.

On June 8, 2022, the Company issued to a third-party investor a conventional note payable(the "Note") with a face value of $162,500. The Note matures June 8, 2023, has a stated interest of 8%. The Note was funded on June 8, 2022, when the Company received proceeds of $150,000 after disbursements for the lender's transaction costs, fees, and expenses.

On June 13, 2022, the Company issued to a third-party investor a conventional note payable (the "Note") with a face value of $265,625. The Note matures June 13, 2023, has a stated interest of 8% The Note was funded on June 13, 2022, when the Company received proceeds of $255,000 after disbursements for the lender's transaction costs, fees, and expenses.

On June 21, 2022, the Company issued to a third-party investor a conventional note payable (the "Note") with a face value of $91,750. The Note matures June 21, 2023, has a stated interest of 8% The Note was funded on June 21, 2022, when the Company received proceeds of $85,000 after disbursements for the lender's transaction costs, fees, and expenses.

On June 23, 2022, the Company issued to a third-party investor a conventional note payable (the "Note") with a face value of $113,335. The Note matures June 23, 2023, has a stated interest of 8% The Note was funded on June 23, 2022, when the Company received proceeds of $105,000 after disbursements for the lender's transaction costs, fees, and expenses.

On May 24, 2022, the Company issued to a third-party investor a conventional note payable (the "Note") with a face value of $600,000. The Note matures May 24, 2023, has a stated interest of 10%. The Note was funded on May 24, 2022, when the Company received proceeds of $600,000. The note is secured by all company’s assets.

On May 24, 2022, the Company issued to a third-party investor a conventional note payable (the "Note") with a face value of $600,000. The Note matures May 24, 2023, has a stated interest of 10%. During period end June 30, 2022, Company received funds in the amount of $300,000. Second half of the note amount was received subsequently to period end. The note is secured by the real property.

On September 30, 2021, the Company entered into an Asset Purchase agreement with iHear Medical, Inc. pursuant to which the Company received a number of intangible assets, equipment, customer database and inventory for a total consideration of 400,000 preferred series C shares and $1,000,000 convertible note. Preferred shares valued at $666,667 on the day of purchase. As part of the acquisition, the Company assumed assets in the amount of $1,666,667, consisting of inventory, equipment, customer lists, patents and other technology-based intangibles.

The Company has evaluated subsequent events through the date the financial statements were issued and filed with the Securities and Exchange Commission. The Company has determined that there are no other such events that warrant disclosure or recognition in the financial statements, except as stated herein.

F-27

Dates Referenced Herein and Documents Incorporated by Reference

This ‘10-K’ Filing	Date	Other Filings

	3/31/24
	1/31/24
	12/31/23
	12/15/23
	6/23/23
	6/21/23
	6/13/23
	6/8/23
	5/24/23
	4/30/23
	4/29/23
	1/13/23
	12/31/22
	12/21/22
	12/11/22
	11/18/22
	11/9/22
	10/28/22
	10/13/22
	9/20/22
Filed on:	9/14/22
	9/13/22
	9/12/22
	8/25/22
	8/22/22
	8/5/22
	7/30/22
	7/6/22
	6/30/22
	6/24/22
	6/23/22
	6/21/22
	6/13/22
	6/8/22
	5/24/22
	4/29/22
	4/6/22
	4/1/22
	3/31/22
	3/30/22
	3/11/22
	2/28/22
	2/25/22
	2/5/22
	1/28/22
	1/18/22
	1/13/22
	12/31/21
	12/21/21
	12/15/21
	11/22/21
	11/15/21
	11/9/21
	10/20/21
	10/13/21
	9/30/21
	9/20/21
	8/25/21
	7/7/21
	4/6/21
	4/1/21
	3/12/21
	2/28/21
	2/25/21
	2/5/21
	1/30/21
	1/23/21
	1/13/21
	1/1/21
For Period end:	12/31/20
	12/15/20
	11/1/20
	10/3/20
	10/1/20
	9/30/20	NT 10-Q
	9/12/20
	8/9/20
	7/1/20
	6/30/20	NT 10-Q
	6/13/20
	5/15/20	8-K
	4/12/20
	4/1/20
	3/31/20	NT 10-Q
	3/20/20
	3/12/20
	3/8/20
	3/1/20
	2/22/20
	1/30/20	8-K
	1/23/20
	1/22/20
	1/1/20
	12/31/19
	12/24/19
	12/15/19
	12/4/19
	12/1/19
	11/18/19
	11/2/19
	11/1/19
	10/28/19
	10/3/19
	10/1/19
	9/30/19	10-Q
	9/12/19	8-K
	8/9/19
	7/1/19
	6/30/19	10-Q, NT 10-Q
	6/13/19
	6/1/19
	5/31/19
	5/15/19
	5/11/19
	5/1/19
	4/15/19
	4/12/19
	4/8/19
	4/1/19
	3/31/19	10-Q, NT 10-Q
	3/27/19
	3/20/19
	3/8/19
	3/2/19
	3/1/19
	2/22/19
	2/1/19
	1/22/19
	1/1/19
	12/31/18	10-K, NT 10-K
	12/26/18
	12/24/18
	12/15/18
	12/7/18
	12/4/18
	12/1/18
	11/2/18
	10/15/18
	10/13/18
	10/10/18
	10/3/18	8-K
	9/10/18
	8/8/18
	7/5/18
	6/4/18	8-K
	5/30/18
	5/23/18
	5/16/18	NT 10-Q
	5/11/18
	4/8/18
	3/27/18
	3/2/18
	2/8/18
	1/1/18
	12/22/17
	12/1/17
	11/10/17
	10/5/17
	8/25/17
	8/18/17
	6/14/17
	5/9/17	8-K
	5/5/17
	2/14/17
	11/15/16	NT 10-Q
	8/1/16
	11/1/13
	6/25/13
	4/1/13
	6/20/12
	6/18/12
	6/15/12
		List all Filings

↑Top

Filing Submission 0001554795-22-000341 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Innerscope Hearing Technologies, Inc. – ‘10-K’ for 12/31/20

On: Wednesday, 9/14/22, at 8:00am ET · For: 12/31/20 · Accession #: 1554795-22-341 · File #: 0-55754

Previous ‘10-K’: ‘10-K’ on 4/16/19 for 12/31/18 · Latest ‘10-K’: This Filing

Annual Report — Form 10-KFiling Table of Contents

‘10-K’ — Annual Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

Annual Report — Form 10-K

Filing Table of Contents